Is Oxytocin “Nature’s Medicine”?  

C. Sue Carter, William M. Kenkel, Evan L. MacLean, Steven R. Wilson, Allison M. Perkeybile, Jason R. Yee, Craig F. Ferris, Hossein P. Nazarloo, Stephen W. Porges, John M. Davis, Jessica J. Connelly, and Marcy A. Kingsbury

Kinsey Institute, Indiana University, Bloomington, Indiana (C.S.C., W.M.K., A.M.P., H.P.N., S.W.P.); School of Anthropology, Department of Psychology, and College of Veterinary Medicine, University of Arizona, Tucson, Arizona (E.L.M.); Department of Chemistry, University of Oslo, Oslo, Norway (S.R.W.); Institute of Animal Welfare Science, University of Veterinary Medicine, Vienna, Austria (J.R.Y.); Departments of Psychology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (C.F.F.); Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois (J.M.D.); Department of Psychology, University of Virginia, Charlottesville, Virginia (J.J.C.); and Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Charleston, Massachusetts (M.A.K.)

Abstract..................................................................................831
Significance Statement ...................................................................831
I. Introduction ..............................................................................831
II. Overview and Challenges.................................................................831
   A. Oxytocin and Vasopressin: an Integrated System 832
III. Discovery of Oxytocin and Vasopressin 833
IV. Evolution as an Organizing Concept ......................................................833
V. Oxytocin-Like Molecules..................................................................835
 VI. Precursors and Fragments of Oxytocin. .....................................................835
   A. Precursors and Extended Forms of Oxytocin 835
   B. Fragments of Oxytocin May Be Biologically Active 835
VII. Processes Regulating Oxytocin and Vasopressin...........................................836
   A. Oxytocin and Vasopressin Are an Integrated System 836
   B. The Structure of These Peptides Identifies Some of the Challenges They Present 836
   C. Feedback Loops ..........................................................................836
   D. Patterns of Peptide Release Matter .................................................836
   E. Individual Differences Are to Be Expected ........................................837
   F. Effects of Other Molecules on the Oxytocin-Vasopressin System.......................837
VIII. Measurement of Oxytocin.................................................................837
   A. Oxytocin Is Difficult to Assay ..........................................................837
   B. Controversy Was Generated by Divergent Findings 837
   C. Disulfide Bonds ...........................................................................838
   D. Salivary Oxytocin ........................................................................838
   E. Can Endogenous Hormone Levels in Bodily Fluids Be Useful in Predicting Responses to Exogenous Oxytocin Treatments? 838
   F. Exogenous Peptides ......................................................................838
   G. Other Measures May Index Receptor Sensitivity ......................................839
IX. Receptors for Oxytocin and Vasopressin......................................................839
   A. The Oxytocin Receptor ................................................................839
   B. Measuring the Oxytocin Receptor ...................................................839
   C. Vasopressin Receptors ................................................................839
   D. Receptor Distributions ..................................................................839
X. Subcellular Signaling Specifies the Functions of Oxytocin and Vasopressin .................840
XI. Genetics and Epigenetics ..................................................................840
XII. Early Experience and Context ...........................................................840

Address correspondence to: C. Sue Carter, 428 Lindley Hall, Indiana University, Bloomington, IN 47405. E-mail: suecarterporges@gmail.com

This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of National Institutes of Health [Grants F32-HD092051, R21-HD095217, R01-HD098117, and P01-HD075750]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

https://doi.org/10.1124/pr.120.019398.
A. Emotional Context Matters .................................................. 840
B. Adversity Versus High Nurture ............................................. 841
C. Vasopressin Systems as Likely Targets for Adversity and Stress in Early Life .................................................. 841
D. Early Exposure to Peptides May Modulate Perceived Context .................................................. 841
E. Birth and Epigenetics .......................................................... 841

XIII. The Autonomic Nervous System as a Target for Oxytocin .................................................. 842
A. Neural and Peptide Interactions Allow a Wide Range of Adaptive Responses .................................................. 842
B. The Autonomic Nervous System Consists of Sympathetic and Parasympathetic Components .................................................. 842
C. The Polyvagal Hypothesis .................................................... 842
D. The Hypothalamus as a Site for Coordination of Vagal-Peptide Interactions .................................................. 842
E. Social Communication and Myelinated Ventral-Vagal Pathways .................................................. 842
F. Cortical Integration of Peptide-Autonomic Interactions .................................................. 843

XIV. Oxytocin and “Stress Coping” .................................................. 843
A. Acute Stress Responses ...................................................... 843
B. Chronic or Traumatic Stress ................................................ 843
C. Myelinated Ventral-Vagal Pathways and Passive Coping .................................................. 843

XV. Immunologic and Anti-Inflammatory Effects of Oxytocin .................................................. 844
A. Oxytocin and Neuroinflammation ........................................ 844
B. Early Experience and Inflammation ..................................... 844
C. Microglia and Macrophage .................................................. 844
D. Oxytocin Protects against Inflammation Associated with Birth .................................................. 846
E. Oxytocin, Oxidative Stress, and Mitochondria .................................................. 846
F. Oxytocin and Gastrointestinal Inflammation .................................................. 847
G. Oxytocin Is Protective to the Developing Gut .................................................. 847
H. Oxytocin and Breast Milk ..................................................... 847
I. Oxytocin and the Healing of Damaged Tissues .................................................. 848
J. Oxytocin and Developmentally Induced Inflammation .................................................. 848
K. Oxytocin, CD38, Immune Function, and Social Behavior .................................................. 849
L. Oxytocin Regulates Probiotic Bacteria .................................... 849
M. Vasopressin and Inflammation ............................................. 849
N. Sex Differences in the Immune System ................................... 849

XVI. Sex Differences .............................................................. 850
A. Sex Differences in Vasopressin ............................................. 850
B. Developmental Effects of Oxytocin and Vasopressin Are Often Sexually Dimorphic .................................................. 850
C. Sex Differences in Response to Stress and Trauma .................................................. 850
D. Sex Differences in Strategies Used to Manage Challenges .................................................. 850
E. Females and Vasopressin ...................................................... 851
F. Sex Differences in Response to Exogenous Peptides .................................................. 851
G. The Stress of Birth ............................................................ 851
H. Gonadal Steroids ............................................................... 851

XVII. Implications for Oxytocin in Mental and Physical Health .................................................. 851
A. Social Support and Perceived Safety ...................................... 851
B. Oxytocin in Psychologic Functioning ..................................... 851

XVIII. Examples of the Complexity Encountered in Treating Disease with Oxytocin-Like Drugs .................................................. 852
A. Postpartum Depression ....................................................... 852
B. Oxytocin and Cancer: a Complex Relationship .................................................. 853

XIX. Pharmacology and Oxytocin: Issues in Therapeutic Applications .................................................. 853
A. The Effects of Oxytocin Are Dose-Dependent .................................................. 853

ABBREVIATIONS: AVP, arginine vasopressin; AVPR, AVP receptor; CADPR, cyclic ADP-ribose; CNS, central nervous system; CRH, corticotropin-releasing hormone; DMX, dorsal motor nucleus of the vagus; Go, guanine nucleotide-binding protein-α; GPCR, G-protein-coupled receptor; HPA, hypothalamic-pituitary-adrenal; IL, interleukin; iNOS, inducible nitric oxide synthase; IRAP, insulin-regulated aminopeptidase; LPS, lipopolysaccharide; MIF-1, melanocyte-inhibiting factor-1; MOR, μ-opioid receptor; MS, mass spectrometry; NF-κB, nuclear factor-κB; OT-X, precursor or extended forms of oxytocin; OXT, oxytocin; OXTR, OXT receptor; PVM, paraventricular nucleus; RAGE, receptor for advanced glycation end products; TNF-α, tumor necrosis factor-α; UPR, unfolded protein response; UPRER, UPR in the endoplasmic reticulum.
Abstract—Oxytocin is a pleiotropic, peptide hormone with broad implications for general health, adaptation, development, reproduction, and social behavior. Endogenous oxytocin and stimulation of the oxytocin receptor support patterns of growth, resilience, and healing. Oxytocin can function as a stress-coping molecule, an anti-inflammatory, and an antioxidant, with protective effects especially in the face of adversity or trauma. Oxytocin influences the autonomic nervous system and the immune system. These properties of oxytocin may help explain the benefits of positive social experiences and have drawn attention to this molecule as a possible therapeutic in a host of disorders. However, as detailed here, the unique chemical properties of oxytocin, including active disulfide bonds, and its capacity to shift chemical forms and bind to other molecules make this molecule difficult to work with and to measure. The effects of oxytocin also are context-dependent, sexually dimorphic, and altered by experience. In part, this is because many of the actions of oxytocin rely on its capacity to interact with the more ancient peptide molecule, vasopressin, and the vasopressin receptors. In addition, oxytocin receptor(s) are epigenetically tuned by experience, especially in early life. Stimulation of G-protein-coupled receptors triggers subcellular cascades allowing these neuropeptides to have multiple functions. The adaptive properties of oxytocin make this ancient molecule of special importance to human evolution as well as modern medicine and health; these same characteristics also present challenges to the use of oxytocin-like molecules as drugs that are only now being recognized.

Significance Statement—Oxytocin is an ancient molecule with a major role in mammalian behavior and health. Although oxytocin has the capacity to act as a “natural medicine” protecting against stress and illness, the unique characteristics of the oxytocin molecule and its receptors and its relationship to a related hormone, vasopressin, have created challenges for its use as a therapeutic drug.

I. Introduction

Oxytocin was the first peptide hormone to be biochemically described and synthesized. This comparatively simple nine–amino acid molecule has been called the “best understood neuropeptide” (Jurek and Neumann, 2018). There is abundant evidence for diverse functions and health benefits for the molecule known as oxytocin. Here we examine the hypothesis that oxytocin and oxytocin-like molecules are components of a “natural medicine” capable of both preventing and treating various disorders and influencing a broad range of diseases.

As background for the current review, it is helpful to recall that the word “medicine” is commonly used in at least two ways, including “the science or practice of the diagnosis, prevention and treatment of disease” or a “compound or drug used for the prevention or treatment of disease.” This review addresses the potential of both endogenous and exogenous oxytocin to serve as medicine in both senses of the word.

Oxytocin has been tested in the treatment of conditions as apparently diverse as autism spectrum disorders, schizophrenia, postpartum depression, anxiety, post-traumatic stress disorders, borderline personality, addiction, pain, metabolic and digestive disorders, diabetes, cardiovascular diseases, cancer, and infectious diseases (to name only a few) (Hurlemann and Grinevich, 2018). Our intent is not to duplicate the massive literature in this field. Rather, from this literature we have attempted to extract basic mechanisms of action of the endogenous oxytocin system and to highlight gaps in knowledge. Awareness of the basic biology of oxytocin actions can help guide the future development of drugs based on this system as well as behavioral interventions for regulating the production and release of endogenous peptides.

II. Overview and Challenges

In June of 2020, a Pubmed search for “oxytocin” yielded over 27,700 articles, most of which were published within the last two decades. Among these articles are thousands of empirical studies and hundreds of recent reviews (Grinevich et al., 2016; Carter, 2017; Carter and Perkeybile, 2018; Hurlemann and Grinevich, 2018; Jurek and Neumann, 2018), with many examining the therapeutic properties of oxytocin.
or oxytocin-like molecules for physical and behavioral disorders. In theory, with so much information it should have been easy to create effective drugs based on the oxytocin system. However, as summarized here, attempts to use oxytocin or oxytocin-like molecules as drugs have faced a variety of obstacles.

A. Oxytocin and Vasopressin: an Integrated System

As summarized below, at least part of the confusion associated with understanding oxytocin arises because this molecule is a component of an ancient and evolved system that includes the related peptide, vasopressin, and its receptors (Carter, 2014, 2017; Carter and Perkeybile, 2018) (Fig. 1; Table 1). Awareness of the characteristics of oxytocin-vasopressin interactions is necessary to address the challenges associated with creating therapeutics based on this system. The oxytocin-vasopressin system interacts with the hypothalamic-pituitary-adrenal (HPA) axis as well as acetylcholine, GABA, glutamate, opioids, cannabinoids, catecholamines, indoleamines, and steroids (Hurlemann and Grinevich, 2018; Jurek and Neumann, 2018). Although they are beyond the scope of this review, these interactions have broad functional consequences that can affect the usefulness of oxytocin-based molecules as “drugs.”

Oxytocin and vasopressin have acute and lasting effects on both the central (Carter, 2014) and autonomic nervous system (Porges, 2012; Quintana et al., 2019). This, in turn, creates another source of complexity, since peptide receptors in the nervous system influence the entire body but also often differ in abundance and localization among individuals and species (Witt et al., 1991; Freeman and Young, 2016; Freeman et al., 2018).

Of particular importance to oxytocin’s capacity to promote health and influence behavior is the growing evidence for actions of oxytocin throughout the immune system and its major role as an anti-inflammatory and antioxidant (Szeto et al., 2011; Bordt et al., 2019; Kingsbury and Bilbo, 2019). Effects on immunity and inflammation suggest another source of apparently “non-specific” effects of oxytocin. Components of the immune system also control the production (CD38) and act as a binding protein regulating the capacity of oxytocin to cross membranes (Yamamoto and Higashida, 2020).

The oxytocin-vasopressin system is “plastic,” and its receptors are sensitive to epigenetic modification across the lifespan, but especially in early life (Kenkel et al., 2019; Perkeybile et al., 2019). Functions of this system are context-dependent and changed by experience, including a history of stress and trauma (Fig. 2). Furthermore, there is evidence, especially in the face of psychologic or physical challenges, that males and females may differ in their response to oxytocin and vasopressin (Carter and Perkeybile, 2018; Jirikowski et al., 2018).

Taken together these factors help to explain why responses to oxytocin-vasopressin pathways may vary among species, among individuals, and by sex. To truly

---

**Fig. 1.** The descent of the neuropeptide ligand and receptor systems through evolutionary time, adapted from Grinevich et al. (2016). Beginning approximately 700 million years ago (MYA), the ancestral peptide and its receptor predate mammals and indeed vertebrates. Both peptide and receptor underwent two rounds of genome duplication approximately 550 MYA. These systems eventually consisted of mesotocin (MS), the mesotocin receptor (MSR), vasotocin (VT), and three vasotocin receptors (VTRs). At the emergence of mammals approximately 200 MYA, the vasotocin peptide and receptor evolved into their modern forms, consisting of AVP and its three receptors (AVPR1A, AVPR1B, and AVPR2). Modern mammalian oxytocin (OXT) and its receptor (OXTR) first evolved approximately 100 MYA.
appreciate oxytocin’s potential as a medicine for a broad range of human disorders, it is useful to recognize these sources of diversity and to briefly review the history of knowledge in this field and the evolution of the oxytocin-vasopressin system.

III. Discovery of Oxytocin and Vasopressin

The pressor function of the pituitary gland was discovered in the late 19th century. In the early 1900s, it was shown that pituitary gland extracts could be used to induce uterine contractions (Dale, 1906), and that milk ejection could be stimulated by pituitary extracts (Mackenzie, 1911). In 1928, Ernst and Berta Scharrer identified the largest cells in the hypothalamus, calling these the “magnocellular neurons” (Scharrer and Scharrer, 1939). However, the behaviorally active chemicals that were secreted by the magnocellular neurons were not identified until Vincent du Vigneaud synthesized oxytocin in 1953 (du Vigneaud et al., 1954) and vasopressin in 1954 (du Vigneaud et al., 1958). Du Vigneaud received the 1955 Nobel Prize in Chemistry for the “first synthesis of a polypeptide hormone.” His Nobel lecture titled “A Trail of Sulfa Research: From Insulin to Oxytocin” set the stage for the understanding that physiologically active hormones were produced not just in the pituitary or peripheral endocrine organs but also in the nervous system. The field of neuroendocrinology arose in part from these discoveries. However, early investigations focused on oxytocin as a “female reproductive hormone” that was involved mainly in birth and lactation. The mistaken notion that oxytocin was only important to one sex (female) and in one context (female reproduction) with no known consequences for males may have slowed initial interest in this molecule.

Studies by de Wied in the 1970s (Kovacs et al., 1979) showed that learning behavior, especially active avoidance, could be affected by oxytocin and vasopressin. In 1979, Pedersen and Prange (1979) demonstrated the ability of oxytocin to facilitate maternal behavior in reproductively naïve female rats. In the 1980s, Keverne and Kendrick (Kendrick et al., 1987) showed that maternal bonding in sheep also depended on oxytocin. A decade later, our own research using the highly social prairie vole revealed a role for oxytocin in adult social behaviors (Witt et al., 1990) in the formation of adult social bonds in both sexes (Williams et al., 1994) and showed for the first time that prairie voles had a novel pattern of distribution of the oxytocin receptors (Witt et al., 1991). Since that time, socially monogamous voles, with many behavioral and physiologic parallels to humans, have become particularly useful for the analysis of the neural, genetic, and epigenetic actions of oxytocin and its receptors (Gobrogge and Wang, 2016; Carter and Perkeybile, 2018; Perkeybile et al., 2019).

IV. Evolution as an Organizing Concept

Understanding the functional versatility of oxytocin requires recognition of the long evolutionary history of the genes that code for vasopressin, oxytocin, and their receptors. More than 600 million years ago, oxytocin-vasopressin–like molecules appeared in the shared ancestors of modern vertebrates and invertebrates (Acher et al., 1995; Knobloch and Grinevich, 2014). Vertebrates emerged approximately 500 million years ago. The signaling properties of the class of molecules
to which the oxytocin and vasopressin receptors belong appeared in this period, and the genes for these receptors are associated with behavioral phenotypes that are consistent among divergent species (Yamashita and Kitano, 2013).

It is interesting to note that aspects of the behavioral patterns elicited by oxytocin-like peptides in modern-day nematodes appear remarkably similar to those found in mammals, suggesting that these peptides are both genetically and functionally conserved (Lockard et al., 2017). Even in nematodes, oxytocin-like molecules regulate a series of behavioral patterns and social interactions necessary for successful mating (Garrison et al., 2012). Moreover, the peptide-stimulated behaviors described in nematodes appeared strikingly similar to those seen in vertebrates.

Vasopressin is more ancient than oxytocin, and vasopressin receptors are sensitive to and regulated by both peptides (Carter, 2017). Both oxytocin and vasopressin arose through duplication from a common ancestral molecule presumed to be vasotocin (Acher et al., 1995; Goodson, 2013). The vasopressin gene currently found in vertebrates appeared over 200 million years ago, and the oxytocin gene appeared over 100 million years ago (Knobloch and Grinevich, 2014; Grinevich et al., 2016). It is estimated that mammalian evolution began around 200 million years ago. Three separate modern receptors for arginine vasopressin (AVP) [AVP receptor (AVPR) 1A, AVPR1B, and AVPR2] and the receptor for oxytocin (OXTR) evolved during the period of mammalian global radiation and expansion (Fig. 1) (Ocampo Daza et al., 2012). The original genes responsible for oxytocin- and vasopressin-like peptides and their receptors are associated with the evolution of behavioral adaptations in modern mammals, including lactation and maternal behavior.

Evolutionarily, more modern functions, including social behavior patterns and reproductive strategies

---

**Fig. 2.** Processing of the oxytocin molecule and its targets. After conversion from the prohormone form, oxytocin exists in an extended form with three extra amino acids. The conversion from extended OXT to oxytocin consisting of nine amino acids occurs with maturation of the hypothalamus in neurotypical individuals. It is not known how this extended form interacts with receptors. In their canonical nine–amino acid forms, both oxytocin and vasopressin bind and act as agonists to both OXTR and AVPR1A, although oxytocin has a higher affinity for OXTR than the AVPR1A, as denoted by the thicker arrow. Oxytocin also acts as an agonist to the pain-sensing transient receptor potential vanilloid-1 (TRPV1) receptor and as a positive allosteric modulator at the MOR. After degradation by IRAP, the C-terminal tail is cleaved from oxytocin to form MIF-1, which can both inhibit MOR and act as an allosteric modulator on the D2 subtype of dopamine receptors (D2R). Oxytocin can also be degraded by other as of yet unspecified peptidase activity into a linear form that stimulates activity of the α-2 type adrenoreceptors (α2ARs). Conventional arrow = agonist; circle-tipped arrow = positive allosteric modulator; block-tipped arrow = antagonist.
found in mammals, may be especially dependent on the effects of oxytocin or related molecules on the oxytocin receptor rather than through actions on the vasopressin receptor (Table 1). Among these is the uniquely mammalian function of milk ejection (Caldwell, 2017). Behaviors associated with selective social memories, high levels of sociality, and social reward necessary for mammalian as well as avian parenting emerged in conjunction with the evolutionary appearance of the oxytocin receptor (Goodson et al., 2012; Kelly and Goodson, 2014). Taken together, the appearance of oxytocin and its receptor set the stage for human evolution (Carter, 2014).

V. Oxytocin-Like Molecules

Oxytocin and vasopressin are small peptides with similar chemical structures (Fig. 2). Classic vertebrate versions of these peptides consist of nine amino acids in a six–amino acid ring formed by cysteine bonds and a three–amino acid tail with a terminal amine. Vasopressin differs in structure from oxytocin by two amino acids. Both oxytocin and vasopressin are synthesized in conjunction with carrier proteins (neurophysin 1 and 2, respectively). The gene for oxytocin is located on human chromosome 20, adjacent to the gene for vasopressin. These genes lie on opposite strands and have opposite transcriptional orientations (toward one another) (Gainer, 2012).

Oxytocin and vasopressin are synthesized in brain regions that are critical to behavioral and physiologic homeostasis. Different cells in specific brain regions produce these two peptides, including the supraoptic nucleus and paraventricular nucleus (PVN) of the hypothalamus (Sannino et al., 2017). The neurons of the PVN, termed magnocellular neurons, which synthesize oxytocin and vasopressin, extend processes to the posterior pituitary gland where these peptides are released into the systemic circulation.

The primary cells of origin of oxytocin also produce networks of neural projections reaching throughout the brain and spinal cord (Grinevich et al., 2016). For example, oxytocin from the PVN can reach the central amygdala with the capacity to quickly modulate emotional functions of the amygdala and brainstem (Stoop, 2012). The PVN is a major site of convergence and integration for neural communication relating to stress with effects on the HPA axis and autonomic functions (Ulrich-Lai and Herman, 2009). Oxytocin is colocalized in at least some of its cells of origin with corticotropin-releasing hormone (CRH), which in turn regulates the HPA axis (Sawchenko and Swanson, 1985). CRH or CRH-vasopressin actions also have been implicated in some of the detrimental effects of chronic stress (Elkabir et al., 1990; Aguilera et al., 2008). Oxytocin may be coreleased with CRH or vasopressin as an adaptive response to a variety of challenges (Neumann and Slattery, 2016) possibly facilitating coping.

Early work on oxytocin and vasopressin suggested that high concentrations of the receptors for these peptides were located in brain regions that were distant from the source nuclei. This led to the hypothesis that within the nervous system, oxytocin and vasopressin were transported by passive diffusion or “volume transmission” (Landgraf and Neumann, 2004). More recently, fine peptide-containing processes have been described throughout the nervous system; these findings support the hypothesis that the peptides are released locally, but peptide also is detected within fibers that reach some distance from the cells of origin (Grinevich et al., 2016; Chini et al., 2017).

VI. Precursors and Fragments of Oxytocin

A. Precursors and Extended Forms of Oxytocin

Precursors, from which the nine–amino acid form of oxytocin is produced, have been shown to be biologically active. The precursors or extended forms of oxytocin, sometimes called OT-X (Fig. 2), consist of 10, 11, or 12 amino acids. Cleavage of the extended form of oxytocin creates the nine–amino acid molecule classically known as oxytocin (Fig. 2). The extended forms of oxytocin likely have many unidentified functions both in adults and during development (de Wied et al., 1991; Gainer, 2012). For example, the extended form of oxytocin is found in mammalian fetuses (Gainer, 2012). Studies in mice also suggest that both oxytocin and the extended form have a critical role in tissue differentiation in the heart and in survival or restoration of heart tissue after damage (such as hypoxia) or disease (such as diabetes) (Gutkowska et al., 2014; Jankowski et al., 2016).

There is one report that the extended form of oxytocin may be elevated in autistic individuals in conjunction with lower-than-normal amounts of the nine–amino acid form of oxytocin (Green et al., 2001), suggesting that a failure to modify the oxytocin precursor could produce a less-active form of the molecule. However, the characteristics and functions of extended forms of oxytocin remain at present poorly understood (Uvnäs Moberg et al., 2019).

B. Fragments of Oxytocin May Be Biologically Active

The nine–amino acid oxytocin molecule also can be further cleaved into other biologically active forms (Fig. 2). As one example, in mouse models of autism, the oxytocin metabolite OT 4–9 has been shown to produce a dose-dependent increase in prosocial behaviors without a change in measures of anxiety (Moy et al., 2019). This effect was seen 24 hours after the termination of a subchronic regimen (2.0 mg/kg of OT 4–9) and persisted for 12 days, suggesting an effect that outlives the presence of the OT 4–9 molecule. Interestingly, OT 5–9 did not affect social behavior.
As originally identified by Kastin (Kheterpal et al., 2009), the N-terminal fragment of oxytocin, proline-leucine-glycine-NH₂ (OT 7-9), is also known as melanocyte-inhibiting factor-1 (MIF-1). Among the functions of MIF-1 is the regulation of pain through interactions with the opioid receptors (Khan et al., 2010). MIF-1 differs from oxytocin in that it is more resistant to degradation and easily passes through the blood-brain barrier. Animal and human research supported the notion that MIF-1 could function as an antidepressant and “endogenous naloxone.” Specifically, MIF-1 decreases the analgesic effect of morphine (Galina and Kastin, 1986; Bocheva and Dzambazova-Maximova, 2004) and acts as a positive allosteric modulator of the D2 and D4 dopamine receptor subtypes (Vartak et al., 2007; Mann et al., 2010). Oxytocin also can be degraded by aminopeptidase activity into a so-called “linear” form (Fig. 2) (Burbach et al., 1980, 1983), and this linear form acts to stimulate α-2 adrenoreceptors (Uvnäs Moberg et al., 2019). The oxytocin system and adrenoreceptors interact in a variety of ways with potential functions that are at present only partially understood (Saniger et al., 2011; Wrazl et al., 2012a,b).

The original use patent for MIF-1 was filed by Abbott Laboratories in the late 1960s, and in 1991, a patentable analog was developed by another company. Although these efforts did not result in medications for reasons described by Ehrensing (2015), in conjunction with more recent animal research, they do offer proof of concept for the functions of oxytocin fragments (Uvnäs Moberg et al., 2019). The creation of MIF-1 from oxytocin is accomplished by insulin-regulated aminopeptidase (IRAP), which thereby regulates the persistence of extracellular oxytocin levels. Thus, when conceiving of oxytocin-signaling equilibria, we must account for not only the relative contributions of ligand and receptor but also degradation via peptidases, such as IRAP. For example, when IRAP is knocked out in male mice, approach to stranger conspecifics is more frequent, suggesting increased oxytocin action (Burns et al., 2019).

VII. Processes Regulating Oxytocin and Vasopressin

A. Oxytocin and Vasopressin Are an Integrated System

The effect of endogenous oxytocin signaling as well as vasopressin and related molecules depends on many factors. These include variation in genetics and epigenetics of the peptides and their various receptors, which may differ across and within species (reviewed by Feldman et al. (2016), Carter and Perkeybile (2018)). Although oxytocin and vasopressin are often studied separately, they function as an integrated system, creating additional levels of complexity (Caldwell and Albers, 2016; Carter, 2017).

B. The Structure of These Peptides Identifies Some of the Challenges They Present

The disulfide bonds in oxytocin and vasopressin are important in explaining the broad biologic consequences of these molecules. These bonds also help to explain the challenges and apparent discrepancies in the measurement of oxytocin and vasopressin (MacLean et al., 2019). Another consideration for understanding and interpreting oxytocin’s effects is the fact that acute versus chronic patterns of oxytocin release can have biologic consequences that also differ. The speed at which these peptides degrade or bind to other molecules is critical to their function. Moreover, the pharmacodynamics of these peptides at their receptors is another essential element in determining their availability (Jurek and Neumann, 2018). In addition, oxytocin and vasopressin differ in their effects on receptor-transduced subcellular signaling cascades (Gulliver et al., 2019).

C. Feedback Loops

Oxytocin-producing cells and OXTR also are sensitive to the oxytocin peptide. Under some conditions, a form of autocrine feedback regulates the functions of oxytocin-producing cells. Stimulation of the oxytocin system, especially in early life, can “feed forward” to release more oxytocin (Bowen et al., 2011; Suraei et al., 2014; Kenkel et al., 2019). Genetic deletion of Oxtr results in lifelong, region-specific changes in oxytocin peptide expression, which speaks to oxytocin’s autorregulation (Vaidyanathan and Hammock, 2020). In some cases, the administration of oxytocin enhances the synthesis of endogenous oxytocin in the central nervous system (Grippo et al., 2012). As described below, the expression of Oxtr in adulthood also is regulated by oxytocin’s actions in early life (Kenkel et al., 2019; Perkeybile et al., 2019). Moreover, availability of OXTRs can be dynamically modulated by increasing exogenous oxytocin administration (Plested and Bernal, 2001; Robinson et al., 2003).

D. Patterns of Peptide Release Matter

The availability and actions of endogenous oxytocin and vasopressin differ by patterns of release or administration. The hypothalamic neurons synthesizing oxytocin exhibit the capacity for pulsatile release. This may be related to a unique morphologic and functional plasticity of these cells, which can change in minutes (Theodosis, 2002; Hatton and Wang, 2008). In adult rats, oxytocin-synthesizing neurons undergo physical transformations in response to hormonal and social stimulation. During pregnancy, birth, and lactation and under other physiologic conditions (such as dehydration or sexual stimulation), glial processes extending from pituicytes (the resident astrocytes of the posterior pituitary) that normally separate the
oxytocin-containing neurons may be retracted, allowing electrical coupling and subsequent stimulus-driven or endogenous pulsatile release of oxytocin. These dynamic neuronal-glial interactions allow for remarkable plasticity that is intricately tuned to hormonal demand for oxytocin (Hatton et al., 1984). Interestingly, vasopressin-containing neurons typically do not show this form of dramatic plasticity and pulsatile release. In the context of labor, this pulsatile release of oxytocin coordinates the intermittent smooth muscle contractions of the uterus that occur by oxytocin binding to OXTRs and the subsequent influx of extracellular calcium (Batra, 1986). Pretreatment with oxytocin or the clinical use of Pitocin (synthetic oxytocin) can cause uterine OXTR desensitization, receptor internalization, and a decreased responsiveness to further oxytocin exposure (Robinson et al., 2003; Gottlieb, 2016). Moreover, compared with continuous exogenous oxytocin exposure, intermittent exposure has been shown to maintain oxytocin-induced uterine contractility and uterine responsiveness, highlighting the importance of oxytocin’s pulsatile release (Talati et al., 2019). It seems likely that oxytocin’s evolutionarily conserved role in smooth muscle contractility during labor (Batra, 1986), milk lactation (Hatton and Wang, 2008), and ejaculation (Filippi et al., 2003; Viveiros et al., 2003) was coadapted for social behavioral functions, such as enhanced mother-infant bonding during birth (Nissen et al., 1995) and lactation as well as selective partner preference formation during sexual intercourse (Carter, 2017). It is possible that the capacity for pulsatile release allows oxytocin to stimulate different receptors and even override some of the actions of vasopressin. Thus, dynamic interactions of oxytocin and vasopressin are important for both the acute and chronic effects of these molecules.

E. Individual Differences Are to Be Expected

In describing individual differences in the actions of oxytocin in humans, it will be important to keep in mind that oxytocin and vasopressin and their receptors are genetically variable, epigenetically regulated, and sensitive to stressors and diet across the lifespan. As one example, salt releases vasopressin and also oxytocin (Leng and Russell, 2019). In addition, nicotine is a potent regulator of vasopressin; thus, smoking, including prenatal exposure of a fetus, holds the potential to adjust this system with effects that likely differ between males and females and that may be transgenerational.

F. Effects of Other Molecules on the Oxytocin-Vasopressin System

Beyond the scope of this review but important to understanding oxytocin and vasopressin is the fact that many other molecules, including dopamine (Wang and Aragona, 2004; Gobrogge and Wang, 2016), serotonin (Dolen, 2015), GABA (Ben-Ari, 2018), and opioids (Meguro et al., 2018), interact with these peptides to influence behavior and other functions. Use of drugs, such as opiates, stimulants, and selective serotonin reuptake inhibitors, and diet, can affect both endogenous oxytocin and its receptors with effects that are largely unknown. In addition, sex differences in oxytocin and vasopressin are common, and it is likely that steroids, including estrogens, androgens (Carter and Perkeybile, 2018; Jirikowski et al., 2018), and glucocorticoids (Liberzon and Young, 1997), play a major role in the regulation of the actions of oxytocin and availability of receptors for oxytocin across the lifecycle. As described below, stress and experiences across the life cycle also have major consequences for the release and actions of oxytocin and vasopressin.

VIII. Measurement of Oxytocin

A. Oxytocin Is Difficult to Assay

Important to the study of oxytocin, even when considering only the classic form, is the capacity to measure this molecule. Initial measurements of oxytocin-using bioassays and radioimmunoassay suggested that oxytocin was typically present in human blood at low concentrations of approximately 5 pg/ml (Leng and Ludwig, 2016), with small pulses in oxytocin release (~15 pg/ml) being sufficient to induce lactation and facilitate uterine contractions in mammals (Saameli, 1963; Leng and Ludwig, 2016). Studies using immunoassay or mass spectrometry (MS) preceded by an extraction procedure continued to detect concentrations in the 5–30 pg/ml range (Szeto et al., 2011; Kagerbauer et al., 2013). However, other methods, including MS, have indicated that endogenous oxytocin may occur in blood at much higher concentrations greater than 500–1000 pg/ml (Kramer et al., 2004; Brandtzæg et al., 2016; MacLean et al., 2017b).

In addition, local tissue concentrations of oxytocin may give results of particular relevance to understanding the beneficial effects of this peptide. For example, within the microenvironment of ovarian tumors, oxytocin levels were measured at 200 times higher than those in plasma (Cuneo et al., 2019). These high levels of oxytocin may reflect a response to the tumor with apparent benefits to reducing inflammation. But they also could be related to the absence within the tumor (compared with blood) of peptide binding molecules, which, in turn, might affect the concentrations of oxytocin detected by antibody-based methods (MacLean et al., 2019; Yamamoto and Higashida, 2020).

B. Controversy Was Generated by Divergent Findings

It was initially suggested that high levels detected by immunoassay were measurement artifacts due to the binding of antibodies to nonhormonal components of blood (Szeto et al., 2011; McCullough et al., 2013).
However, recent work indicates that oxytocin readily engages in complexes at its disulfide bridge (Avanti et al., 2013) and that the vast majority of oxytocin in biosamples evades detection using conventional approaches to measurement (Brandtzaeg et al., 2016). Importantly, these findings have been confirmed using MS—which is highly specific compared with immunoassay—suggesting that earlier critiques of the high oxytocin concentrations detected by immunoassay (which were within concentration ranges deemed implausible) may have been misguided. However, despite its advantages regarding specificity, MS-based methods for measuring oxytocin are still in active development, and many researchers have faced substantial challenges for reliable detection of oxytocin using this approach. For example, Brandtzaeg et al. (2016) struggled to reproduce earlier MS-based methods for measurement of unbound oxytocin. Furthermore, Franke et al. (2019) have argued that Brandtzaeg et al.’s method may have been significantly affected by the lower resolution MS instrument used. Hence, it is important to keep in mind that although MS is a very sophisticated approach, the verdict on the optimal measurement method is still being debated. Additional areas in which MS measurement of oxytocin can be improved include the removal of interferents (e.g., phospholipids, which can suppress signals, resulting in vast underestimation of oxytocin concentrations), automation (including sample preparation) for higher throughput, and further development/maturation of high-sensitivity microfluidic separation systems (e.g., nano liquid chromatography).

The dynamic factors that affect the measurement of oxytocin and vasopressin also can influence attempts to create a pharmacology based on oxytocin. At present, measurements of peptides have suffered from poor specification regarding the forms in which researchers intend to detect oxytocin; this is, in part, because the biologic significance of different states of oxytocin remains poorly understood. Current work suggests that oxytocin and vasopressin are dynamically changing in biologic matrices, such as blood. In addition, detecting the presence of binding molecules will be critical to accurate representations of the availability of these elusive molecules (Yamamoto and Higashida, 2020).

C. Disulfide Bonds

Disulfide bonds in the cysteines of both oxytocin and vasopressin allow these molecules to be highly reactive, forming relatively temporary unions with other molecules. Furthermore, oxytocin may be quickly sequestered by binding to other abundant thiol-containing molecules, such as glutathione as well as phospholipids and cellular elements, such as blood cells that are discarded in the creation of plasma. This binding of nonapeptides to other molecules could be influenced by temperature, pH, availability of oxygen, other factors in the medium being studied, or methods in use (MacLean et al., 2019). These dynamics may explain at least some of the unique properties of oxytocin and vasopressin but also account for problems associated with in vivo measurement of oxytocin and vasopressin. For example, common approaches to sample preparation, such as solid-phase extraction, likely discard the majority of oxytocin in blood (Brandtzaeg et al., 2016; MacLean et al., 2019). Thus, measurements in blood in particular introduce many other factors that can affect peptide determinations.

D. Salivary Oxytocin

Salivary measurements, possibly with fewer sources of variation, offer an alternative for the assessment of changes in oxytocin (Carter et al., 2007; White-Traut et al., 2009; Bernhard et al., 2018; MacLean et al., 2018). Several studies have revealed reliable variations in oxytocin concentration, especially in rapid response to specific experiences, such as anticipation of breast feeding (White-Traut et al., 2009), sexual stimulation, exercise, affiliative social contact, and psychologic stress (Jong et al., 2015; MacLean et al., 2017a). However, the relationships between concentrations of peptides in saliva, blood, and peptide concentrations in the source brain nuclei are not yet well-understood (Quintana et al., 2018).

E. Can Endogenous Hormone Levels in Bodily Fluids Be Useful in Predicting Responses to Exogenous Oxytocin Treatments?

Knowledge of endogenous oxytocin or vasopressin concentrations is important to predicting the consequences of exogenous oxytocin exposure. Such assessments are rarely made, in part because of the difficulties associated with the measurement of oxytocin (MacLean et al., 2019). However, at least in autism spectrum disorders, measurements of endogenous oxytocin (Parker et al., 2017) and especially vasopressin (Carson et al., 2015; Oztan et al., 2018a) did predict behavioral sensitivity to exogenous hormone treatments. Comparatively low levels of vasopressin (but not oxytocin) measured in neonatal cerebrospinal fluid have been associated with a subsequent diagnosis of autism (Oztan et al., 2020). In another recent example, relative concentrations of endogenous oxytocin and vasopressin in plasma were associated with sex, age, anxiety, attachment behaviors, and cognition (Plasencia et al., 2019). These studies support the usefulness of measurements of both oxytocin and vasopressin but leave many empirical questions unresolved.

F. Exogenous Peptides

One of the most remarkable aspects of pharmacological studies of the effects of exogenous oxytocin or related drugs is the fact that these compounds are being given to humans—with a few notable exceptions—without attempts to measure either endogenous oxytocin or vasopressin. The measurement of endogenous oxytocin has indeed proven
difficult and contentious but is not impossible (MacLean et al., 2019). Doses of exogenous oxytocin have the potential to either be ineffectively low or nonspecifically high (see oxytocin’s ability to act on the AVPR1A, below), particularly when these doses are not informed by endogenous concentrations and release patterns.

G. Other Measures May Index Receptor Sensitivity

Most studies of receptors are limited to genetic markers or in rare circumstances made in postmortem tissues (Bao and Swaab, 2018). For example, age-related reductions in receptors for oxytocin have been detected in postmortem brain tissues from individuals with autism (Freeman et al., 2018). However, as described below, proxies for the status of oxytocin and vasopressin receptors, including measures of methylation levels in receptor genes, also may predict reactions to endogenous or exogenous oxytocin (Lancaster et al., 2015; Ebner et al., 2019). Thus, there is usefulness in measuring both the availability of oxytocin and the sensitivity of receptors that are capable of responding to this molecule (see below).

IX. Receptors for Oxytocin and Vasopressin

A. The Oxytocin Receptor

Only one oxytocin receptor has been described (OXTR), the gene for which is located in humans on chromosome 3p24–26 (Gimpl and Fahrenholz, 2001; Jurek and Neumann, 2018). The OXTR gene encodes a G-protein–coupled receptor (GPCR) with a seven-transmembrane domain. The same oxytocin receptor is present in neural tissue and in other parts of the body, such as the uterus, breast, and gastrointestinal tract.

Although there is technically only one OXTR, it is now understood that oxytocin affects numerous different GPCRs (Fig. 2). Oxytocin can bind to receptors that were identified in vitro, such as OXTR, but also to vasopressin receptors (AVPR1A, AVPR1B, AVPR2) (de Wied et al., 1991; Peter et al., 1995; Ragnauth et al., 2004; Manning et al., 2008; Ocampo Daza et al., 2012). In general, oxytocin (vs. vasopressin) has its highest affinity for OXTR. However, oxytocin also readily binds to AVPR1A (reviewed in Song and Albers (2018)). Outside these two neuropeptide systems, recent research has found several other targets for oxytocin’s effects. For example, oxytocin acts as an agonist on the pain-sensing transient receptor potential vanilloid-1 receptor, where it attenuates nociception and drives nocifensive behavior (Nersesyan et al., 2017; Wee et al., 2019). Oxytocin also acts as a positive allosteric modulator of the μ-opioid receptor (MOR) (Meguro et al., 2018), where it likely furthers antinociception.

B. Measuring the Oxytocin Receptor

The measurement of peptide receptors is problematic because the pharmacological tools that are available for identifying, stimulating, or blocking receptors for oxytocin and vasopressin may not be sufficiently selective to allow easy identification or manipulations of these receptors, especially in vivo (Busnelli and Chini, 2018). Cell culture or other in vitro methods do not necessarily reflect the functional availability of these peptides, especially since the binding that occurs in vivo, including in blood or tissues, could be influenced by competing molecules that differ from one test condition to another (Yamamoto et al., 2019). For example, as described below, microglial OXTR has been difficult to detect in vivo but appears to be significantly upregulated after immune challenges/stressors, especially when microglia and macrophages are challenged in vitro (Yuan et al., 2016; Szeto et al., 2017).

C. Vasopressin Receptors

The three vasopressin receptor subtypes respond to oxytocin to varying degrees. These are expressed in different tissues, and their genes are located on separate chromosomes. AVPR1A is found in the nervous system and throughout the cardiovascular system with a broad set of behavioral functions. AVPR1B is found in the pituitary but also in brain areas with a role in the management of stress and aggression (Vaccari et al., 1998; Stevenson and Caldwell, 2012). AVPR2 is localized primarily to the kidney with a classic role in fluid balance. Functional effects of oxytocin and vasopressin depend on interactions with both OXTR and AVPR1A (Song et al., 2014; Hicks et al., 2015; Carter, 2017; Chini et al., 2017; Song and Albers, 2018).

D. Receptor Distributions

Receptors for both oxytocin and vasopressin are localized in areas of the nervous system that regulate social, emotional, and adaptive behaviors, including the amygdala, the HPA axis, and the autonomic nervous system (Quintana and Guastella, 2020). Based on work primarily in rodents and birds, among the regions with especially high levels of OXTR are various parts of the amygdala, the bed nucleus of the stria terminalis, the nucleus accumbens, brainstem source nuclei for the autonomic nervous system, and in systems that regulate the HPA axis as well as in brainstem tissues involved in pain and social attention (Stoop et al., 2015; Freeman and Young, 2016; Wilson et al., 2016; Gobrogge et al., 2017; Poisbeau et al., 2018). OXTR is also found in various cortical areas and the hippocampus, brain areas that are especially variable among species and individuals, with possible consequences for behavioral plasticity (Witt et al., 1991; Grunewald et al., 2012; Seelke et al., 2016a,b; Duchemin et al., 2017).

Both individual and species differences in OXTR and AVPR1A distributions are commonly identified and presumably adaptive (Witt et al., 1991; Hammock and Young, 2005; Freeman and Young, 2016; Okhovat et al., 2017; Ophir, 2017; Carter and Perkeybile, 2018; Okhovat...
et al., 2018). Species variation is likely important in the evolution of different patterns of sociality, including those that differentiate socially monogamous from non-monogamous rodent species (Carter and Perkeybile, 2018) and affiliative versus nonaffiliative avian species (Goodson et al., 2006; Wilson et al., 2016). However, regional distributions of CNS OXTR in primates, including humans, have proven challenging to identify and interpret (Freeman and Young, 2016).

X. Subcellular Signaling Specifies the Functions of Oxytocin and Vasopressin

Oxytocin acts via GPCRs to activate subcellular cascades with eventual effects on transcription factors (Busnelli and Chini, 2018; Jurek and Neumann, 2018). Knowledge of the subcellular signaling pathways that respond to the stimulation of oxytocin or vasopressin receptors are among the next generation of approaches to the creation of medicines based on oxytocin pathways (Lerman et al., 2018; Gulliver et al., 2019; Kingsbury and Bilbo, 2019). Genes for OXTR and the three vasopressin receptors code for separate GPCRs, each with a seven-transmembrane domain. The subcellular signaling pathways vary among receptors. In addition, the capacity of oxytocin and vasopressin to activate a given receptor subcellular signaling pathway may differ according to the concentrations of the peptides and based on variations in the regional location of receptors in the nervous system (Stoop et al., 2015; Chini et al., 2017; Busnelli and Chini, 2018; Song and Albers, 2018). Differences in subcellular signaling could help to explain the capacity of oxytocin and vasopressin to have different functions in various tissues, such as those regulating birth (Arrowsmith and Wray, 2014), social behavior (Caldwell and Albers, 2016; Song et al., 2016), reactivity to stressors (Murgatroyd and Nephew, 2013; Stoop et al., 2015; Neumann and Slattery, 2016), cancer (Lerman et al., 2018), and cardiovascular disease (Reiss et al., 2019).

When given as an exogenous treatment, the behavioral consequences of oxytocin are dose-dependent but not typically linear (Ceanga et al., 2010; Klein et al., 2011, 2013; Borland et al., 2019). As with other peptide-based treatments acting on GPCRs, more is rarely better. This may explain several of the unexpected or paradoxical findings reported when oxytocin is given as an exogenous treatment (Carter, 2017; Song and Albers, 2018). The lack of a full understanding of the subcellular pathways through which oxytocin and vasopressin function is at present a barrier to using these nonapeptides as medicines. Furthermore, as mentioned above, the oxytocin and vasopressin-like molecules exist in several endogenous forms, and the signaling functions of precursors or fragments of these peptides have only begun to be described.

XI. Genetics and Epigenetics

A reduction or upregulation in the availability of the oxytocin or vasopressin receptors can reflect both heritable genetic variation (King et al., 2016; Baker et al., 2017) and/or epigenetic tuning (Okhovat et al., 2015; Baker et al., 2017; Okhovat et al., 2018; Towers et al., 2018; Perkeybile et al., 2019) of this system. The variable expression in tissues of OXTR is also epigenetically tuned by early life experience (Baker et al., 2017; Krol et al., 2019a; Perkeybile et al., 2019), increasing the capacity of peptides to have complex adaptive functions. Evidence in humans for the functional importance of the oxytocin genetic-epigenetic systems at present comes primarily from correlations among genetic and epigenetic variations in the OXTR gene and individual differences in behavior, physiology, and brain anatomy (Rodrigues et al., 2009; Tost et al., 2010; Jack et al., 2012; Puglia et al., 2015; Lancaster et al., 2018).

Genetic variations in the OXTR, indexed by single-nucleotide polymorphisms, were originally related to autism spectrum disorders (for example, variant rs2254298 G>A and rs53676 G>A) (Jacob et al., 2007). The OXTR gene can be silenced via DNA methylation, thus reducing the expression of the oxytocin receptor (Kusui et al., 2001). Functional relationships between methylation of the oxytocin receptor gene and behavior were first detected in autism (Gregory et al., 2009) and recently validated (Andari et al., 2020). Such relationships have also been found in other conditions, including postpartum depression (Bell et al., 2015) and schizophrenia (Rubin et al., 2014). In neurotypical humans, methylation status of the OXTR also has been shown to strongly predict measures of social perception in both college-aged adults and infants (Jack et al., 2012; Puglia et al., 2015, 2018; Krol et al., 2019b). Specific single-nucleotide polymorphisms could be implicated in a variety of functions through epigenetic and intergenerational effects on the expression of OXTR (Bell et al., 2015; Chagnon et al., 2015). Below, we discuss how experiences in early life, including parental care and oxytocin administration in the context of obstetric care, can program epigenetically the OXTR system to produce lifelong changes in this system.

XII. Early Experience and Context

A. Emotional Context Matters

This is in part because context can influence physiology, helping to create individual differences in the capacity to react to environmental events. As one example, behavioral changes induced by early experience may reflect changes in the oxytocin system. Human research, especially studies conducted in individuals with a history of personal adversity, suggest that in some contexts, exogenous oxytocin can have
asocial or negative consequences (Bartz et al., 2010), including the increased perception of threat in the presence of individuals from other social groups (De Dreu, 2012). In terms of early experience, positive parenting (vs. neglect) has lasting beneficial consequences for behavior and health in the offspring, possibly also through retuning of the oxytocin/vasopressin pathways.

B. Adversity Versus High Nurture

Animal research also suggests that the nature of early experience can influence the development of oxytocin/vasopressin pathways and subsequent long-term behavioral outcomes. For instance, adversity in early life has the capacity to sensitize the vasopressin system and, in some cases, upregulate AVPR1A in brain regions involved with defensive behaviors (Carter, 2017). Alternatively, early life exposure to highly nurturant parenting or as little as a single exposure to exogenous oxytocin produces epigenetic changes in Oxtr (Kenkel et al., 2019; Krol et al., 2019a; Perkeybile et al., 2019). Receptor changes such as these can have long-lasting consequences for the capacity for sociality and emotional regulation (Carter, 2003; Carter et al., 2009; Kenkel et al., 2019).

C. Vasopressin Systems as Likely Targets for Adversity and Stress in Early Life

Expression of vasopressin or the vasopressin receptors also are likely to be affected by negative social experiences, including neglect or maltreatment in early life (Bunck et al., 2009; Hernandez et al., 2016). Under conditions in which the vasopressin system is sensitized, especially in a context of fear or danger, we can hypothesize that oxytocin could stimulate the vasopressin receptor. Thus, early adversity or maltreatment might dysregulate or upregulate vasopressin, the vasopressin receptor, or other factors regulating this system, including catecholamines. This switch from oxytocinergic to vasopressinergic stimulation in turn would alter the ability to cope with a challenge. In later life, it could encourage either a more active or mobilized defensive or aggressive behavioral strategy possibly accompanied by anxiety. In cases of severe traumatic stress, a more energetically conservative “shut-down” strategy might emerge, characterized by immobility due to fear rather than mobilization. It is likely that dynamic interactions between oxytocin and vasopressin allow behavioral, autonomic, and emotional-state shifts between anxiety and depression, such as those that characterize a history of trauma (see below).

D. Early Exposure to Peptides May Modulate Perceived Context

In individuals with a history of adversity or trauma, the effects of exogenous oxytocin may appear to be detrimental [for example, Walsh et al. (2018)]. Once more, we can hypothesize that the apparently paradoxical effects of oxytocin in responses to extreme stressors represent, in part, the capacity of oxytocin to stimulate AVPR1A and AVPR1B (Fig. 3) (Caldwell, 2017; Carter, 2017). This may be of particular importance in individuals primed by negative experience. For example, even small amounts of oxytocin might be capable of activating vasopressin receptors, with effects that involve mobilization and potentially defensive emotional or behavioral responses. Based on data from oxytocin knockout mice, in which the vasopressin system is sensitized (Ragnauth et al., 2004), we can also hypothesize that individuals with low concentrations of endogenous oxytocin might be more likely to experience increased vasopressin-like activities when given oxytocin (Carter, 2017).

E. Birth and Epigenetics

Data from animal models and human epidemiology indicate that widely used medical interventions (i.e., exogenous oxytocin, such as Pitocin given to facilitate labor, opioid medications that block the oxytocin system, or cesarean sections that alter exposure to endogenous oxytocin), have lasting consequences for the offspring and/or mother (Hayes and Weinstein, 2008; Kroll-Desrosiers et al., 2017; Kingsbury and Bilbo, 2019). Such exposures hold the potential to have epigenetic effects on the oxytocin systems, including changes in DNA methylation (Kenkel et al., 2019). These changes in turn would have lasting effects on the expression of receptors for oxytocin, leaving individuals differentially able to respond to oxytocin and also possibly to the effects of vasopressin. For instance, in a recent study intended to model labor induction, voles exposed indirectly to oxytocin at birth (via maternal administration) show changes in Oxtr methylation patterns in the fetal brain, a gregarious phenotype of social behavior, and sex- and region-specific changes in OXTR and AVPR1A densities in the brain as adults (Kenkel...
et al., 2019). Deconstructing the developmental benefits of endogenous oxytocin and the implications of exogenous exposure to this peptide has much to teach us about the biology of health versus disease.

XIII. The Autonomic Nervous System as a Target for Oxytocin

A. Neural and Peptide Interactions Allow a Wide Range of Adaptive Responses

Understanding the complex actions of oxytocin requires awareness that oxytocin regulates not only the brain and reproductive system but also the immune (see below) and autonomic nervous systems. Effects on the autonomic nervous system include shifts in state and emotional regulation and can be seen as acute changes as well as chronic adjustments that affect the entire body. For example, evidence supporting the coordinated effects of acetylcholine (the major neurotransmitter in the parasympathetic nervous system) and oxytocin comes from colocalization of these molecules and their receptors in tissues, including hypothalamic and brainstem areas, that regulate the autonomic nervous system (Freeman and Young, 2016; Quintana et al., 2019). Interactions between oxytocin and the autonomic nervous system are also relevant under conditions in which the system is manipulated pharmacologically. For example, treatment with exogenous oxytocin induces increases in vagal activity as measured by respiratory sinus arrhythmia (Quintana et al., 2013).

B. The Autonomic Nervous System Consists of Sympathetic and Parasympathetic Components

The sympahtoadrenal axis is associated with flight-fight responses. Under extreme stress or life-threatening situations, both oxytocin and vasopressin activate sympathetic and parasympathetic pathways, with a more variable autonomic response in the face of milder stressors (Porges, 2012; Yee et al., 2016).

The parasympathetic nervous system and specifically vagal pathways have important consequences for brain and cognitive function. The vagus also plays a particularly important role in the neural regulation of the mammalian immune system (Dantzer, 2018). It is likely that these peptides integrate the activity of different branches of the autonomic nervous system, which helps to explain the importance of social attachment in protecting against or modulating different forms of emotion dysregulation. These same peptides, together with the vagus nerve, have effects on the immune and metabolic systems across the lifespan, which also helps to explain the lasting effects of early emotional experiences on physical health and well-being (Hammock, 2015; Amini-Khoei et al., 2017; Kingsbury and Bilbo, 2019).

C. The Polyvagal Hypothesis

The autonomic nervous system supports the physiologic and metabolic demands of the cerebral cortex and is necessary for social behavior (Porges, 2009, 2012). Embedded within the mammalian parasympathetic nervous system/vagus nerve are two systems: a more ancient unmyelinated branch of the vagus with cells that originate within the brainstem region known as the dorsal vagal complex and with pathways to subdiaphragmatic organs but also innervating the heart. In addition, encased within the vagus nerve, as it exits the brainstem, is a more evolutionarily modern myelinated vagal system; cells for this branch originate in the ventral-vagal complex, with pathways to the heart and bronchi. The ventral-vagal pathways interact with the brainstem nuclei that innervate the striated muscles regulating the face and head; these may be of particular relevance to social communication as well as the anti-inflammatory actions of oxytocin (Dantzer, 2018, Kingsbury and Bilbo, 2019).

Oxytocin receptors are especially abundant in brainstem regions, including the dorsal vagal complex or dorsal motor nucleus of the vagus (DMX) that regulates subdiaphragmatic organs. Stimulation of the DMX slows the heart. Vagal regulation is also implicated in sexual and social behaviors and is linked with motivation and reward circuitry (Han et al., 2018). Oxytocin may act on these ancient and highly conserved brainstem regions to permit mammalian patterns of maternal and sexual behavior that require immobility without fear (Porges, 1998; Kenkel et al., 2013).

D. The Hypothalamus as a Site for Coordination of Vagal-Peptide Interactions

The PVN of the hypothalamus is both a major site of oxytocin synthesis and a key area that responds to oxytocin, presumably via input from oxytocin receptors (Quintana et al., 2019). Furthermore, the PVN is a regulatory center for autonomic functions, particularly vagal functions (Herman et al., 2012). The visceral target organs of the autonomic nervous system, such as the heart, digestive, and immune systems, also contain abundant receptors for oxytocin (Welch et al., 2005; Gutowska and Jankowski, 2012; Jurek and Neumann, 2018; Wang et al., 2019). Thus, it is not surprising that in the face of stress oxytocin can protect the functions of the digestive system (Yang et al., 2019), heart (Gutowska and Jankowski, 2012; Buemann and Uvnas-Moberg, 2020), and immune system (Kingsbury and Bilbo, 2019).

E. Social Communication and Myelinated Ventral-Vagal Pathways

The muscles of the mammalian face and head are regulated by the same brainstem area that also regulates the myelinated vagal pathway, thus linking
through bidirectional communication the heart with facial expressions and intonation of vocalizations. This integrated social engagement system provides mechanisms through which emotional experience and physiologic states are involved in social communication. Autonomic actions of oxytocin as well as vasopressin also influence the capacity for and expression of social bonds that arise in response to challenge or adversity (DeVries et al., 1996; Cho et al., 1999).

Oxytocin acting via the autonomic nervous system and acting on the cortex and brainstem has been repeatedly implicated in human social engagement, facially expressed emotions, and eye gaze (Kemp et al., 2012; Quintana et al., 2013; Freeman and Young, 2016). Evidence from rodents indicates that the oxytocin receptor plays an important role in cortical functions necessary for social cognition (Ophir, 2017), social reward (Song et al., 2014), and social affective behavior (Rogers-Carter et al., 2018; Rogers-Carter and Christianson, 2019). At least some of these effects also involve interactions between oxytocin and dopamine (Quintana et al., 2019; Martins et al., 2020). Moreover, the modulation of social approach behavior by PVN oxytocin release onto ventral tegmental area dopaminergic neurons is dependent on gut-brain signaling through the vagus nerve (Sgritta et al., 2019).

F. Cortical Integration of Peptide-Autonomic Interactions

The insular cortex, a multisensory processing region that also contains a rich population of OXTRs, functions to integrate external sensory stimuli with internal visceral, emotional, and motivational states (Rogers-Carter and Christianson, 2019). Specifically, the “visceral insular cortex,” which receives input from gastric mechanoreceptors, arterial chemoreceptors, and cardiovascular baroreceptors, respiratory centers, and the vagus nerve, plays a central role in interoception (Barnabi and Cechetto, 2001). This region of cortex is able to detect changes in internal state, influencing appropriate social responses, such as approach versus avoidance behavior with a stressed conspecific (Rogers-Carter et al., 2018).

XIV. Oxytocin and “Stress Coping”

Many of the emotional, visceral, and immune effects of oxytocin and vasopressin rely on interactive actions of these molecules on the autonomic pathways. These effects are adaptive in the face of stressful experiences, although the functions of these peptides as well as hormones of the HPA axis are different under conditions of acute versus chronic stress (Table 1).

A. Acute Stress Responses

Adaptive responses to acute stressors have a distinct physiology from those elicited by chronic stress (Pournajafi-Nazarloo et al., 2011; Bosch and Young, 2018). In many cases reactions to acute stressors include the release of oxytocin, possibly in anticipation of more chronic situations that may follow (Lang et al., 1983; Gibbs, 1986; Engert et al., 2016). These anticipatory responses also may include increases in social behavior and transient changes in other organ systems, including the heart (Grippo et al., 2012; Kemp et al., 2012).

B. Chronic or Traumatic Stress

Oxytocin has particular importance in the face of chronic stress when “stress-coping” effects may take precedent. Oxytocin can facilitate passive forms of coping and protect against shutting down or “immobilization with fear” (Porges, 1998). Behavioral, physiologic, and anatomic data from rodents (Grippo et al., 2009) and humans (Grewen and Light, 2011) suggest that chronic, antistress effects of social support can downregulate the sympathetic nervous system, allowing the expression of protective and restorative functions of the vagal systems (Thompson et al., 2008; Yee et al., 2016).

C. Myelinated Ventral-Vagal Pathways and Passive Coping

Studies in prairie voles have revealed that oxytocin has protective actions on the autonomic functions of the ventral, myelinated vagus, as measured by changes in neutrally regulated heart rate variability (respiratory sinus arrhythmia) (Grippo et al., 2009). Oxytocin also may directly co-opt the older unmyelinated vagus through receptors in the dorsal vagal complex, protecting mammals from responding to threat with a more primitive “reptile-like” freezing pattern and evacuation of the lower bowel (Porges, 2012).

Immobility with fear or freezing, associated with traumatic experiences, can be a component of despair and depression. This response is adaptive in conserving energy. But freezing in fear is not optimal for other functions, such as active social behaviors that rely on mobilization and high levels of metabolic activity (Porges, 2012). The capacity of oxytocin to protect this system is critical to the types of social engagements that characterize mammalian social behavior, including birth and parenting.

Mammals, with their comparatively large brains, are particularly vulnerable to the need for oxygen. Under traumatic conditions, the functions of oxytocin may allow a shift to those necessary for protection of the survival of cortical processing. However, when oxygen is insufficient, psychologic dissociation (Li et al., 2020) or even loss of consciousness can occur (Carter, 2014). As one example, oxytocin levels were exceptionally high in women with a history of trauma who showed a pattern of dissociation, supporting the
hypothesis that elevations in oxytocin can be adaptive in trauma (Seng et al., 2013).

As described below, oxytocin, in part through effects on the vagus nerve, has direct and indirect effects on the immune and metabolic systems across the lifespan. These actions also help to explain the lasting effects of early emotional experiences on physical health and well-being (Hammock, 2015; Engert et al., 2016; Amini-Khoei et al., 2017; Quintana et al., 2017; Kingsbury and Bilbo, 2019).

**XV. Immunologic and Anti-Inflammatory Effects of Oxytocin**

Oxytocin has central roles in immune surveillance and immunologic homeostasis and supports resistance to a whole host of immune challenges, stressors, and insults across a range of body tissues (Li et al., 2017b; Buemann and Uvnäs-Moberg, 2020). Many of the protective effects of oxytocin observed across the lifespan appear to be mediated through the OXTR and occur in response to both normal adaptive stressors during development (e.g., birth, gut microbial colonization) and in response to injury and trauma (Kingsbury and Bilbo, 2019). Furthermore, although oxytocin can influence immune-system development (Geenen, 2006; Murgatroyd et al., 2016; Rotondo et al., 2016; Li et al., 2017b), such as being highly concentrated in the thymus and playing a role in the “education” of thymic cells for self-tolerance (Geenen, 2006), we focus here on oxytocin’s anti-inflammatory roles in the context of immune-system function and homeostatic cellular processes.

**A. Oxytocin and Neuroinflammation**

The role of oxytocin as an important regulator of the mammalian immune system (Li et al., 2017b; Kingsbury and Bilbo, 2019) that ties social behavior and experiences with the capacity to heal in the face of stress or trauma is especially evident within the nervous system (Fig. 4). In an adult animal model of ischemic stroke, animals subjected to focal cerebral ischemia have reduced tissue damage, increased anti-oxidant activity, and decreased oxidative stress if they are socially housed during the recovery period, as opposed to animals that recover in social isolation (Karelina et al., 2011). These effects of social housing are mediated by oxytocin, as the administration of exogenous oxytocin to experimental animals recovering in social isolation recapitulates the neuroprotective effects; OXTR antagonism blocks this protection in both socially housed and socially isolated animals (Karelina et al., 2011). Similarly, in a model of acute brain inflammation induced by a systemic injection of the bacterial endotoxin lipopolysaccharide (LPS), intranasal administration of oxytocin 1 hour prior to the LPS injection reduces microglial activation, the levels of proinflammatory cytokines TNF-α and IL-1β, and the levels of proinflammatory mediators cyclooxygenase-2 and iNOS. These effects were detected in the prefrontal cortex of LPS-treated adult male mice, as compared with LPS-treated males that received intranasal vehicle (Yuan et al., 2016). Interestingly, oxytocin has no effect on these inflammatory measures in the absence of LPS exposure, suggesting that oxytocin’s anti-inflammatory actions require the presence of a stressor. Remarkably similar effects of oxytocin were observed in healthy men subjected to an immune challenge (Clodi et al., 2008). Compared with men administered LPS alone, men who received intravenous infusion of LPS plus oxytocin had an attenuated endocrine, cytokine, and chemokine response to the immune challenge. Taken together, these findings demonstrate that oxytocin can lessen the inflammatory response induced by LPS across species.

**B. Early Experience and Inflammation**

In animals subjected to early life adversity, oxytocin also has protective effects (i.e., boosts resilience) later in life against subsequent stressors or immune challenges through a reduction in brain inflammatory processes (Amini-Khoei et al., 2017; Mairesse et al., 2019) (Fig. 4). For instance, male mice subjected to maternal separation stress during the first 2 weeks of life are characterized by a depressive-like phenotype in adulthood during a forced swim test, sucrose preference test, and grooming assay. This depressive phenotype is accompanied by impaired mitochondrial function, reduced antioxidant activity, increased oxidative stress, and increased gene expression for immune-proinflammatory markers, all within the hippocampus (Amini-Khoei et al., 2017). Importantly, the depressive-like phenotype and the accompanying inflammation were attenuated if male mice were injected intracerebroventricularly with oxytocin in adulthood but not if the OXTR antagonist, atosiban, was administered alongside oxytocin. Similar findings were observed for mice subjected to a low-protein diet during gestation to simulate fetal growth restriction, a condition associated with the development of cerebral palsy, cognitive, and behavior deficits. In this model, subsequent postnatal injections of the inflammatory cytokine IL-1β cause increased expression of classic and nonclassic proinflammatory genes within microglia, decreased myelination, decreased brain connectivity, and increased anxiety-like behavior (Mairesse et al., 2019). When carbocetin, a long-lasting OXTR agonist, was administered postnatally alongside IL-1β, it attenuated the microglial proinflammatory gene expression, reversed the myelination and connectivity deficits, and normalized anxiety-like behavior.

**C. Microglia and Macrophage**

Many of oxytocin’s anti-inflammatory actions appear to be, at least in part, through the attenuation of
inflammatory processes mediated by microglia and macrophages (Karelina et al., 2011; Yuan et al., 2016; Li et al., 2017b; Szeto et al., 2017; Mairesse et al., 2019) (Fig. 4). OXTR is present on the cell surface of microglia as well as neurons and astrocytes; the addition of oxytocin to microglia cultures stimulated with LPS dampens the expression of major histocompatibility complex class II, a gene that is induced within activated microglia (Karelina et al., 2011). Similarly, both Oxtr mRNA and OXTR protein are enriched in primary microglia stimulated with LPS, and treatment of these microglial cultures with oxytocin suppresses the LPS-induced production of TNF-α and IL-1β (Yuan et al., 2016). After an LPS immune challenge in vivo, oxytocin also reduces the expression and production of proinflammatory cytokines TNF-α and IL-1β as well as the number of prefrontal cortex cells labeled with ionized calcium-binding adapter molecule 1, a microglial marker (Yuan et al., 2016). In microglia cultures isolated from both animals exposed to an inflammatory low-protein diet during gestation and control animals injected with IL-1β and interferon α (proinflammatory mediators), the oxytocin agonist carbetocin reduces the morphologic changes associated with microglia activation as well as the expression of proinflammatory mediators IL-6, TNF-α, and iNOS (Mairesse et al., 2019). These effects are mediated through OXTR, as addition of an OXTR antagonist (L-368899) prevents the microglial morphologic changes and the attenuation of IL-6, TNF-α, and iNOS expression. Given the ancient conserved functions of oxytocin, it is perhaps not surprising that carbetocin has similar immune suppressive effects on microglia morphology and cytokine release in zebrafish in vivo after an inflammatory stimulus (Mairesse et al., 2019). Similarly, an additional ancient function of oxytocin is the protection against painful stimuli, including a behavior response that alleviates stress. Within zebrafish, hypothalamic oxytocin neurons drive
nocifensive behavior after the exposure to a noxious stimulus, suggesting a conserved stress-coping mechanism of oxytocin (Wee et al., 2019). Moreover, in mammals, oxytocin cells in the PVN control acute inflammatory pain perception, whereas oxytocin in the spinal cord controls nociception, and oxytocin in the amygdala regulates the processing of emotional pain (Poisbeau et al., 2018).

Whereas oxytocin dampens inflammatory processes mediated by microglia, the tissue-resident macrophages of the CNS, similar effects are observed for oxytocin acting on macrophages outside of the CNS (Fig. 4). For instance, THP-1 and human primary macrophages stimulated with LPS upregulate OXTR expression and protein production relative to nonstimulated cells (Szeto et al., 2017). LPS treatment also upregulates IL-6 mRNA and protein in THP-1 macrophages and murine macrophages (including tissue-resident murine peritoneal macrophages), and this effect is attenuated when THP-1 cells are pretreated with oxytocin (Szeto et al., 2017). Furthermore, blocking NF-κB activation prevents this upregulation of Otxr and IL-6 expression, suggesting that the OXTR acts as an acute phase protein that reduces macrophage-mediated inflammatory responses both within and outside of the CNS. Interestingly, LPS challenge downregulates AVPR2 in primary human macrophages, and pretreatment of THP-1 cells with vasopressin has no effect on LPS-induced IL-6 secretion, highlighting the anti-inflammatory function of oxytocin as opposed to vasopressin (Szeto et al., 2017).

D. Oxytocin Protects against Inflammation Associated with Birth

Oxytocin also plays a significant anti-inflammatory role at birth protecting the fetal brain against the hypoxic-like conditions that accompany labor (reviewed in Kingsbury and Bilbo (2019); Fig. 4). It also likely preserves mitochondrial function (Kaneko et al., 2016), potentially by acting on the mitochondrial unfolded protein response (Bordt et al., 2019). The process of parturition is considered an inflammatory/immune event in which offspring are exposed to reduced oxygen and blood flow (Lagercrantz and Slotkin, 1986; Tyzio et al., 2006; Maron et al., 2010), a surge in stress hormones (Lagercrantz and Slotkin, 1986), elevated fetal cytokines (Castillo-Ruiz et al., 2018), and antigen colonization (Costello et al., 2012; Castillo-Ruiz et al., 2018). Under hypoxic-ischemic conditions, oxytocin has been shown to confer neuroprotection to fetal tissue on the day of birth by reducing the metabolic demand of neurons through a dramatic and precise switch in GABAergic signaling that attenuates the elevation of intracellular chloride (Tyzio et al., 2006; Khazipov et al., 2008). This oxytocin-mediated switch delays the time to anoxic depolarization, a process of accelerated cell death that is characterized by significant increases in oxidative stress and reactive oxygen species (Tyzio et al., 2006; Khazipov et al., 2008). In rodent models of autism wherein this oxytocin-mediated switch is absent at birth, offspring are characterized by altered social behaviors and neuronal hyperexcitability, demonstrating that oxytocin’s neuroprotective effects during a major inflammatory event give rise to appropriate social behaviors in adolescence (Tyzio et al., 2014). However, oxytocin appears to have dose-dependent effects at birth, particularly when administered exogenously, with higher doses conferring less neuroprotection in vitro (Ceanga et al., 2010) as well as an increased risk for autism for male offspring (Soltys et al., 2020). Possible explanations to explain the loss of oxytocin’s protection when administered exogenously at high concentrations are oxytocin-induced receptor desensitization (Plsted and Bernal, 2001; Robinson et al., 2003) and/or oxygen desaturation of the fetal blood supply (i.e., greater hypoxia) that can occur after synthetic oxytocin-induced uterine hyperstimulation (Simpson and James, 2008). A third explanation may be the promiscuous binding of oxytocin to the vasopressin receptor AVPRI A when administered exogenously at high doses, as AVPRI A can mediate proinflammatory signaling (Bordt et al., 2019) and exacerbate neural toxicity during hypoxia/hypoglycemia (Tanaka et al., 1994; Spoljaric et al., 2017). Thus, the protective nature of endogenous versus exogenous oxytocin as well as its dose-dependent effects at birth require further study given the widespread use of synthetic oxytocin to manage labor.

E. Oxytocin, Oxidative Stress, and Mitochondria

Oxytocin also protects neural cells against hypoxic-ischemic conditions by preserving mitochondrial function, reducing oxidative stress, and decreasing a chromatin protein that is released during inflammation (Kaneko et al., 2016), which can activate microglia through the receptor for advanced glycation end products (RAGE) (Massey et al., 2019; Yamamoto and Higashida, 2020). All of these effects are abolished in the presence of OXTR antagonism (Tyzio et al., 2006; Ceanga et al., 2010; Kaneko et al., 2016) and are consistent with the anti-inflammatory and neuroprotective functions of oxytocin signaling during hypoxic-ischemic events, including birth. Moreover, the serum of pregnant women administered the OXTR antagonist atosiban for preterm labor displays an increase in oxidative stress and a decrease in antioxidant capacity compared with women in preterm labor who did not receive atosiban (Grzesiak et al., 2018). Similarly, the plasma of offspring born to pregnant rats treated with atosiban is characterized by increased oxidative stress compared with the plasma of offspring born to saline-injected mothers (Simsek et al., 2012). Finally, term babies born to mothers who underwent elective cesarean sections at term are characterized by
significantly lower levels of serum oxytocin at birth as compared with vaginally delivered infants (Marchini et al., 1988), suggesting a reduction in the protective, anti-inflammatory actions of oxytocin with cesarean deliveries.

**F. Oxytocin and Gastrointestinal Inflammation**

A rich literature demonstrates that oxytocin also acts as an anti-inflammatory protective molecule for the adult and developing gastrointestinal system, including the period of gut microbial colonization at birth and lactation during which the fetal gut is exposed to significant antigen stimulation from thousands of bacterial species (reviewed in Kingsbury and Bilbo (2019)) (Fig. 5). Within adult rodents, stress- and/or chemical-induced colitis increases intestinal damage, oxidative stress, neutrophil infiltration, the expression of inflammatory pathway genes, and anxiety-related behavior (Iseri et al., 2008; Cetinel et al., 2010; Welch et al., 2014). Oxytocin treatment dampens the severity of intestinal damage and alleviates anxiety, whereas co-administration of an OXTR antagonist or the use of Oxtr knockout mice prevents oxytocin’s protective effects (Iseri et al., 2008; Cetinel et al., 2010; Welch et al., 2014). Similar to offering neuroprotection to the brain during hypoxic-ischemic events, oxytocin appears to protect the gut during reduced intestinal blood flow within a model of burn-induced gastric injury (Iseri et al., 2008). Thermal burns produce transient splanchnic vasoconstriction followed by oxidative and nitrosative intestinal injury and increased reperfusion injury and, if severe enough, increased intestinal permeability, sepsis, and organ failure (Iseri et al., 2008). Whereas rats exposed to a thermal burn followed by a subcutaneous saline injection are characterized by greater levels of malondialdehyde and myeloperoxidase activity, greater gastric neutrophil infiltration, and greater microscopic damage scores of the gastric mucosa and skin, experimental rats that received two subcutaneous injections of oxytocin had a significant attenuation of skin damage and burn-induced oxidative damage of the intestinal mucosa (Iseri et al., 2008). Furthermore, Erdman and colleagues have shown that the gut bacterium, *Lactobacillus reuteri*, acting through vagal nerve stimulation promotes the endogenous release of oxytocin, which functions to accelerate wound healing of the skin by activating CD4+Foxp3+CD25+ immune regulatory T cells (Poutahidis et al., 2013; Varian et al., 2017). Moreover, in a rodent model of necrotizing enterocolitis induced by formula feeding, maternal separation, and intermittent hypoxia, oxytocin administration decreases the severity of intestinal inflammation, whereas the OXTR antagonist exacerbates it (Gross Margolis et al., 2017). Oxytocin also reduces visceral hypersensitivity, a feature of intestinal bowel syndrome (Xu et al., 2018) and diabetic polyneuropathy (Erbas et al., 2017), and attenuates stress-induced GI motility disorders (Yang et al., 2019).

**G. Oxytocin Is Protective to the Developing Gut**

The increased expression of OXTR in enteric neurons and enterocytes in intestinal tissue coincides with the periods of birth and lactation, a time when the fetal gut is simultaneously exposed to both endogenous maternal oxytocin (via maternal release at birth and during breastfeeding) and inflammatory processes, such as amino acid–insufficiency stress, bacterial antigen stimulation, and microbial colonization (Welch et al., 2009; Klein et al., 2017; Kingsbury and Bilbo, 2019). The absence of Oxtr during development in Oxtr knockout mice results in increased intestinal inflammation in addition to increased macromolecular gut permeability, increased gut motility, and disruption of mucosal maintenance (Welch et al., 2014), indicating that the oxytocin-signaling system has important functions for the establishment of the gastrointestinal system. Specifically, oxytocin signaling has been shown to reduce cellular stress within Caco2BB cells, a human gut cell line used as an enterocyte model, by modulating the unfolded protein response (UPR) in the endoplasmic reticulum (UPRER) (Klein et al., 2013, 2014, 2016). The UPRER can be activated during inflammation or immune challenges or in response to other stressors (Bordt et al., 2019) and is a cellular stress response that occurs when there is a buildup of unfolded and/or misfolded proteins within the endoplasmic reticulum of cells. This accumulation of proteins activates the UPRER, which serves to trigger signaling cascades that halt protein synthesis, reduce protein load, and restore cellular homeostasis (Schroder and Kaufman, 2005; Hetz et al., 2011; Hetz, 2012). In addition to the UPRER, oxytocin also modulates autophagy, a process in which cellular components are degraded and recycled to restore homeostasis (Klein et al., 2014).

**H. Oxytocin and Breast Milk**

In an effort to simulate the exposure of developing enterocytes to bacterial endotoxin via breast milk, Klein et al. (2016) treated Caco2BB cells with LPS. Whereas LPS increased NF-κB proinflammatory signaling and suppressed the UPRER within Caco2BB cells, oxytocin treatment prevented these LPS-mediated effects (Klein et al., 2016). This led Klein and associates (Klein et al., 2017) to propose that, during the lactation period, oxytocin in colostrum and breast milk both protects enterocytes from apoptotic cell death amid low level antigen microbial stimulation and modulates cellular metabolism via phasic UPR runs to promote enterocyte cell differentiation. Klein et al. (2017) further showed that both colostrum oxytocin and exogenous oxytocin protect primary intestinal rat villi at birth from cellular stress induced by amino acid starvation, a period of nutrient insufficiency between birth and first feeding.
Specifically, oxytocin dampens inflammatory process, halts protein translation, and promotes autophagy in newborn intestinal villi.

I. Oxytocin and the Healing of Damaged Tissues

In addition to its protective role for developing and adult gastrointestinal tissue, endogenous oxytocin, at high levels, has been implicated in human wound healing (Gouin et al., 2010) and is protective against cardiovascular dysfunction via a suppression of inflammatory processes mediated by neutrophils, macrophages, T lymphocytes, TNF-α, and IL-6 (Jankowski et al., 2016; Reiss et al., 2019). Among other commonly studied models in which oxytocin has been shown to be anti-inflammatory are those involving the healing of tissue flaps (Xu et al., 2017) and ovarian cancer (Cuneo et al., 2019). Within human patients, higher levels of ascites oxytocin were associated with lower levels of the proinflammatory cytokine IL-6 and a significant survival advantage. Moreover, oxytocin inhibited IL-6 production in cancer cell lines (Cuneo et al., 2019). Oxytocin also may restore tissue after procedures that damage the nervous system, intestines, and cardiovascular system (Karelina and DeVries, 2011; Bordt et al., 2019; Kingsbury and Bilbo, 2019). Interestingly, some of oxytocin’s wound-healing properties are mediated via vagal nerve stimulation by the intestinal bacteria *L. reuteri*, which causes an elevation in PVN oxytocin followed by an increase in systemic oxytocin (Varian et al., 2017).

J. Oxytocin and Developmentally Induced Inflammation

Benefits of oxytocin are often seen in developmental rodent models, such as maternal separation or pharmacological or genetic models capable of creating animals with atypical patterns of social behavior and associated elevations in inflammation. Neonatal rodents respond with increases in inflammation after nutrient insufficiency, maternal separation, or injections that induce inflammation (Klein et al., 2018). In all of these cases, there is evidence that oxytocin is protective. Atypical behaviors, tissue damage, and microglial activation can be reduced by oxytocin treatments (Wang et al., 2018; Zinni et al., 2018; Mairesse et al., 2019).
K. Oxytocin, CD38, Immune Function, and Social Behavior

Previous as well as recent findings suggest that some of oxytocin’s protective effects on immune function and social behaviors are mediated by CD38. CD38 is a well-known immune marker that is expressed by a range of immune cells (T cells, B cells, macrophages, natural killer cells), is involved in the proliferation and immune responses of lymphocytes, and serves as a diagnostic marker for lymphoma, leukemia, myeloma, and human immunodeficiency virus infection (Malavasi et al., 2008). Within the brain, CD38 is a transmembrane receptor on hypothalamic neurons that catalyzes the formation of cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate from NAD⁺ and NAD phosphate (Deaglio and Malavasi, 2006). These molecules play an integral role in the regulation of intracellular Ca²⁺ and control highly conserved processes, such as egg fertilization, muscle contraction, hormone secretion, and immune function (Malavasi et al., 2008). In the hypothalamus, both cADPR and nicotinic acid adenine dinucleotide phosphate serve to increase intracellular Ca²⁺, thereby triggering the central and peripheral release of oxytocin that is important for a variety of social behaviors (Higashida et al., 2012). Within CD38 knockout mice, neuroanatomical findings are consistent with deficits in hypothalamic oxytocin secretion, and females show defects in maternal care, whereas males display social memory impairments (Jin et al., 2007). These social behaviors were rescued by subcutaneous OT injections or CD38 re-expression (Jin et al., 2007). Within humans, single-nucleotide polymorphisms of the CD38 gene have been associated with oxytocin inhibition and an increased risk for autism (Lerer et al., 2010; Higashida et al., 2012), a disorder characterized by immune dysfunction (McDougle et al., 2015). Moreover, human lymphoblastic cell lines derived from autistic patients show reduced CD38 expression compared with those derived from nonautistic controls (Lerer et al., 2010). Recent research also suggests that autism risk associated with vitamin A deficiency may be mediated through the CD38–oxytocin pathway (Gamlieil et al., 2016; Lai et al., 2018). In an intriguing review by Higashida et al. (2018), evidence is put forth that hypothalamic oxytocin secretion is increased after social stress in subordinate animals via a CD38-cADPR-dependent mobilization of Ca²⁺ from intracellular stores and after hyperthermia (triggered by LPS endotoxin exposure, social stress, or stress coping) via a transient receptor potential melastatin-2–dependent influx of Ca²⁺. Higashida et al. (2018) elaborate on how stress-induced oxytocin release caused by fever may explain the transient recovery of social functions within autistic individuals during hyperthermia (Zhong et al., 2016), similar to how exogenous OT administration has been reported to improve social behavioral deficits within autistic patients and animal models (Higashida et al., 2018). Intriguingly, this model helps explain our earlier findings of greater hypothalamic oxytocin-Fos colocalization in subordinate and nonsocial stressed finches (Goodson et al., 2015) as well as the facilitation of partner preference formation in LPS-injected female prairie voles (Bilbo et al., 1999).

L. Oxytocin Regulates Probiotic Bacteria

Other treatments that may act through oxytocin include the benefits of probiotic bacteria, such as L. reuteri (Erdman and Poutahidis, 2016; Šgritta et al., 2019), found in colostrum and breast milk (Klein et al., 2010, 2011). Furthermore, like oxytocin, vasopressin has roles for immune-system development, yet vasopressin signaling exacerbates inflammatory processes in the brain after ischemic stroke and traumatic brain injury (Szmydynger-Chodobska et al., 2010, 2011). In addition, oxytocin signaling may play a more limited role in immune-system regulation and in some cases can function to augment oxytocin’s related immune effects (Li et al., 2017b).

M. Vasopressin and Inflammation

Vasopressin and AVPR1A have also been implicated in immune function with effects that, in general, are proinflammatory and often opposite in direction from those of oxytocin (Li et al., 2017b; Bordt et al., 2019). For instance, vasopressin signaling exacerates inflammatory processes in the brain after ischemic stroke and traumatic brain injury (Szmydynger-Chodobska et al., 2010, 2011). Furthermore, like oxytocin, vasopressin has roles for immune-system development, yet vasopressin may play a more limited role in immune-system regulation and in some cases can function to augment oxytocin’s related immune effects (Li et al., 2017b).

N. Sex Differences in the Immune System

As detailed below, recent research also links sex differences and sexual differentiation to the immune system (McCarthy et al., 2017; Dantzer, 2018, 2019). These effects differ according to the social history of the individual, contributing to what has been termed “context” (Bartz et al., 2010; Carter, 2017). These effects also differ in physiology, with females more protected than males in the context of stressors, such as birth, because of their perinatal hormonal status and an inherently greater antioxidant capacity within their brains (Kingsbury and Bilbo, 2019). Thus, these effects likely give rise to differences in how males and females
respond to the protective functions of endogenous and exogenous oxytocin.

**XVI. Sex Differences**

Oxytocin and vasopressin are produced by both males and females; however, the functions of these peptides vary between sexes and among species (Carter and Perkeybile, 2018). Because of the adaptive nature of these hormonal systems and the fact that sexual differentiation is influenced by genetics, epigenetics, and physiologic processes (including inflammation) across the lifespan (McCarthy et al., 2017), the relationship between sex and peptides is not very well-understood. Steroids, including estrogen and testosterone of either endogenous or exogenous origins, can influence both oxytocin and vasopressin as well as the expression of their receptors (Jirikowski et al., 2018). The study of sex differences in oxytocin and vasopressin is further complicated by dynamic changes in steroids that are experienced in both sexes across the lifecycle.

A thorough description of factors regulating sex differences is beyond the scope of this review, although this topic is discussed in some depth in earlier reviews from our group (Carter, 2003, 2014, 2017; Carter et al., 2009; Carter and Perkeybile, 2018; Kenkel et al., 2019). However, knowledge of sex differences with regard to the functions of oxytocin and vasopressin is greatly needed in the development of peptide-based treatments for mental and physical disorders, including substance abuse, schizophrenia, and trauma (Macdonald, 2013). This is particularly important since, for several of these disorders, one sex often has greater vulnerability for social and cognitive dysfunction.

**A. Sex Differences in Vasopressin**

Effects of vasopressin are often more apparent in males versus females. Of particular relevance to understanding interactions between oxytocin and vasopressin is the consistent finding that vasopressin in the nervous system is affected by androgens. In rodent brains, endogenous vasopressin synthesis is androgen-dependent and sexually dimorphic within an axis that modulates self-defensive behavior (de Vries and Forger, 2015; Dumais and Veenema, 2016). Vasopressin receptors also vary regionally between males and females (DiBenedictis et al., 2017).

Responses to exogenous vasopressin also can differ in males and females (Dantzer, 1998; Thompson et al., 2006; Carter et al., 2009). However, vasopressin also functions in conjunction with oxytocin to facilitate selective social behaviors, including social bonds and selective aggression (Cho et al., 1999; Carter, 2017).

**B. Developmental Effects of Oxytocin and Vasopressin Are Often Sexually Dimorphic**

Adding to the complexity of the sex differences in these peptides are findings that indicate that the presence of oxytocin or vasopressin during development can modify both of these peptides and their receptors. During development, the vasopressin receptors appear to be particularly sensitive to tuning by exogenous peptides, with effects that also differ between males and females. For example, research in voles indicates that vasopressin and its receptors can be developmentally regulated by exposure to exogenous oxytocin, thus contributing to altered capacity to form pair bonds (Bales et al., 2007). In both sexes, exposure to a relatively low dose of exogenous oxytocin shortly after birth reduces the expression of AVPR1A in several other brain areas (Bales et al., 2007). However, in male prairie voles, the same treatment increases the expression of vasopressin receptors in the ventral pallidum, a brain region associated with reward and pair bonding. In another experiment in prairie voles using a wide range of doses of vasopressin, dose-dependent increases in vasopressin in the 1st week of life were followed by increases in aggression in adulthood. These effects on aggression, necessary for mate guarding, also were most pronounced in males (Stribley and Carter, 1999).

**C. Sex Differences in Response to Stress and Trauma**

Sex differences in the oxytocin-vasopressin system often are most apparent in the face of stressful experiences, including social and hormonal experiences in early life (Carter et al., 2009; Kenkel et al., 2019). Glucocorticoids and other hormones released during stressful experiences also can have major effects on oxytocin, and oxytocin can act to moderate the release of and effects of glucocorticoids. For example, glucocorticoids and exposure to stressors have been shown to upregulate the oxytocin receptor (Liberzon and Young, 1997).

**D. Sex Differences in Strategies Used to Manage Challenges**

We can speculate that activation of central vasopressin or its receptors and associated increases in the sympathetic nervous system would allow more active or mobilized responses to emotional and physiologic challenge including the capacity for aggression and physical violence. For example, it is possible that a male-biased dependence on vasopressin might help explain the capacity of male prairie voles to form social bonds in the face of extreme challenges, whereas stress inhibits heterosexual pair-bond formation in females (DeVries et al., 1996). Dependence on vasopressin would leave males more capable of responding to challenges associated with defending the family using mobilized responses. However, if generalized to other species, this sex difference may also leave males more vulnerable to disorders or injury associated with increased aggression and risk taking (Carter, 1998, 2007; Dantzer, 2018). Concurrently, males appear to be protected against shut-down responses, especially in life-threatening situations, via vasopressin...
and associated increases in alertness or arousal in the face of threats.

E. Females and Vasopressin

Females also produce and rely on the physiologic effects of vasopressin. However, females are significantly more vulnerable to disorders associated with shut-down responses or immobilization, such as depression and post-traumatic stress disorder. In general, in adulthood females also may be more dependent on estrogen and estrogen-oxytocin interactions. Thus, in the presence of deficiencies in either oxytocin or its receptor, females may be more vulnerable to disorders, including symptoms of depression, characterized by either generalized anxiety or passive responses. For example, female humans also are at least twice as likely to be victims of trauma or other adversities, which in turn can increase later vulnerability to emotional disorders (Altemus et al., 2014).

F. Sex Differences in Response to Exogenous Peptides

The consequences of treatment with exogenous peptides can vary by sex in humans (Thompson et al., 2006; Domes et al., 2010; Taylor et al., 2010), nonhuman primates (Jiang and Platt, 2018), and other mammals (De Vries and Panzica, 2006; Carter, 2007; Albers, 2015; Okhovat et al., 2018). In postmenopausal women, increases in endogenous oxytocin have been associated with “gaps in social relationships” (Taylor et al., 2006). Releasing oxytocin may be a component of a self-regulatory process that helps mammals deal with isolation, stress coping, and recovery from trauma. For example, female prairie voles subjected to a 1-hour immobilization stress recovered faster in the presence of their male partner as opposed to recovering alone, displaying less anxiety-like behavior, lower levels of the stress hormone corticosterone, and increased PVN oxytocin release (Smith and Wang, 2014). Furthermore, the benefits of this oxytocin-mediated social buffering were recapitulated in stressed females that were subsequently isolated after they received injections of oxytocin in the PVN (rather than access to their partner) (Smith and Wang, 2014). These hormonal responses could also facilitate subsequent social engagement and relationships as well as boost the immune system (see below), functions that would be especially adaptive in females who may be less able than males to survive alone (Taylor et al., 2010).

G. The Stress of Birth

Oxytocin may be of special relevance in helping infants (Tyzio et al., 2006, 2008) and mothers recover from the trauma of birth while simultaneously engaging in mother-infant bonding (Nissen et al., 1995). For instance, there are peaks in serum oxytocin immediately postpartum in women that correspond with the expulsion of the placenta, contractions to reduce uterine bleeding, and an early “sensitive” period for mother-infant bonding (Nissen et al., 1995).

H. Gonadal Steroids

Species variation also reflects differential sensitivity to gonadal steroids among mammals. For example, behavioral patterns in socially monogamous species may be particularly reliant on peptides, including oxytocin and vasopressin, whereas fewer social species, especially males of nonmonogamous species, seem more behaviorally dependent on gonadal steroids, including androgens (Carter and Perkeybile, 2018). Adaptive variations in the relative importance of steroids and peptides are critical to understanding the origins of species and sex differences but also may help in understanding individual differences in the consequences of treatments with exogenous molecules.

XVII. Implications for Oxytocin in Mental and Physical Health

A. Social Support and Perceived Safety

The effects of endogenous oxytocin and vasopressin on brain-body connections, including the immune and autonomic nervous system may help to explain the profound health-related effects of social relationships or their absence. Despite the complexity associated with using exogenous peptides as medicines, there has been considerable optimism generated by short-term behavioral effects of oxytocin. Oxytocin appears to be of special relevance to physical and mental protective adaptations that involve high levels of sociality or social support and a sense of psychologic safety as well as emotional regulation and autonomic stability that are necessary for mental health and higher levels of cognitive functions (Carter, 2014).

B. Oxytocin in Psychologic Functioning

A recurring issue in attempts to use oxytocin as a medicine is the need to understand its role in behavioral and physiologic adaptations and resilience in the face of stressors and trauma. Nervous system activity, neural connectivity, and responses to social stimuli have been related to peripheral peptide concentrations in both neurotypical individuals (Lancaster et al., 2018a) and those diagnosed with various mental illnesses, such as schizophrenia or bipolar disorder (Rubin et al., 2018). Peripheral levels of oxytocin and vasopressin or variations in their receptors have been associated with function in Williams syndrome (Dai et al., 2012), autism spectrum disorders (Oztan et al., 2018b), schizophrenia (Rubin et al., 2014, 2018), depression (Cyransowski et al., 2008; Goekoop et al., 2011), postpartum depression (Zelkowitz et al., 2014; Bell et al., 2015), borderline personality disorders (Brune, 2016), eating disorders (Aulinas et al., 2019), and substance abuse (Buisman-Pijlman et al., 2014).
XVIII. Examples of the Complexity Encountered in Treating Disease with Oxytocin-Like Drugs

A large scientific literature, beyond the scope of this review, has implicated oxytocin in both health and illness. However, the relationships between endogenous and responses to exogenous oxytocin have not been easily identified. In some individuals and for a subset of disorders, the effects of exogenous oxytocin have been negative. Below, we offer examples of the complexity associated with the use of oxytocin as a therapeutic in postpartum depression and cancer. Among the sources of variation in outcomes are genetics, epigenetics, and especially adversity in early life. In addition, as described below in the case of cancer, effects of oxytocin on different subcellular signaling pathways will need to be considered in creating safe medicines based on oxytocin-like molecules.

A. Postpartum Depression

Because of its central role in birth and lactation, oxytocin was a logical target as an explanation for and treatment of postpartum depression. We hypothesized that endogenous oxytocin, including that released as a consequence of lactation, would be protective against the development of postpartum mood shifts, possibly in part by reducing susceptibility to social or environmental stressors (Carter and Altemus, 1997). There is increasing experimental evidence for this hypothesis (Gust et al., 2020).

Comparatively lower concentrations of plasma oxytocin, both prenatally and postpartum, have been associated with increased symptomology (Skrundz et al., 2011; Stuebe et al., 2013; Cox et al., 2015; Garfield et al., 2015). Specific polymorphisms within both OXT (Jonas et al., 2013) and OXTR (Apter-Levy et al., 2013; Mileva-Seitz et al., 2013) also appear to confer vulnerability to developing postpartum depression. Women with higher reported levels of psychosocial stress in early pregnancy and postpartum had lower depressive symptoms if they had higher levels of circulating oxytocin (Zelkowitz et al., 2014). In addition, epigenetic modification of OXTR via DNA methylation at specific CpG sites in the promoter region also increased the risk of postpartum depression, with effects that were expressed in a genotype-specific manner (Bell et al., 2015).

However, there is considerable individual variation in oxytocin concentrations and in the oxytocin receptor in pregnancy and postpartum. It is possible that knowledge of these differences, especially in the context of individual variations in life history, as well as the specific levels of peptides and receptors for both oxytocin and vasopressin, can be used to predict or treat disorders, such as postpartum depression. Furthermore, in humans it appears that the adult response to exogenous oxytocin is mediated by early life experiences including trauma (Walsh et al., 2018). The release of endogenous oxytocin also has been related to early childhood abuse, with generally lower levels in individuals who have experienced greater emotional adversity in early life (Heim et al., 2009; Toepfer et al., 2017). Moreover, the release of oxytocin differs according to the adult attachment style of the individual. In one study, oxytocin levels were elevated in trauma survivors, supporting the hypothesis that oxytocin serves a “stress-coping” function. However, a lower level of increase in oxytocin in response to a stressor was seen in individuals with a “dismissive” attachment style compared with more securely attached individuals (Pierrehumbert et al., 2012). However, “secure” attachment or a “sense of safety,” as used in psychologic research, is a theoretical construct, which must be translated into physiologic states. The relationship between oxytocin and trauma in adulthood has not yielded consistent results (Engel et al., 2019), and perhaps a fuller consideration of early life experience could resolve this. Thus, psychologic context can manifest as physiology, with consequences for the actions of oxytocin and vasopressin; this of course complicates the attempts to study these peptides in clinical populations.

The effects of the relationship between oxytocin and the symptoms of postpartum depression are particularly obvious in women experiencing stress (Zelkowitz et al., 2014; Massey et al., 2016) or with a history of adversity (Walsh et al., 2018). Furthermore, early life stress and the emotional history of an individual can influence the reaction to exogenous oxytocin. For example, in a placebo-controlled experiment, intranasal oxytocin was administered to women diagnosed with postpartum depression (Walsh et al., 2018). In that study, oxytocin decreased symptoms in women who did not have a history of early life stress but increased symptoms in women with a history of stress.

Depression, used in a more general sense, also has proven difficult to reliably relate to endogenous oxytocin. Several studies show a decrease in peripheral oxytocin with increased depressive symptoms (Frasch et al., 1995; Scantamburlo et al., 2007; Ozsoy et al., 2009; Seay et al., 2014). However, individuals with increased depressive symptoms sometimes exhibit increased levels of oxytocin (Parker et al., 2010; Holt-Lunstad et al., 2011; Seay et al., 2014). Furthermore, high levels of oxytocin-staining cells have been detected in postmortem tissue; people with major depressive disorder had a greater number of oxytocin and vasopressin-immunoreactive cells in the PVN compared with controls (Purba et al., 1996). There are also reports of increased variability in oxytocin levels in people with depressive symptoms compared with controls (van Londen et al., 1997; Cyranowski et al., 2008). Studies such as these suggest dysregulation in the oxytocin-vasopressin system possibly associated with stressful experiences across the lifespan and the emotional experiences described as major depression (Bao and Swaab, 2018). These studies also illustrate the challenges associated with using oxytocin as therapy for behavioral disorders.
B. Oxytocin and Cancer: a Complex Relationship

The use of oxytocin as a pharmaceutical also requires attention to possible physical side effects of prolonged exposure to this molecule. In many physical disorders, including cancer, social support is associated with reduced risk of disease progression (Hinzey et al., 2016). Lactation has long been associated with reductions in breast cancer (Lerman et al., 2018). In these cases, oxytocin is a plausible protective mechanism. For example, a variety of experiments, including animal research and in vitro studies supports the hypothesis that oxytocin can inhibit tumor growth in breast cancer. In addition, breast tumor growth is inhibited (or perhaps prevented) by exercise, another effect that has been attributed to the capacity of exercise to release oxytocin (Alizadeh et al., 2018).

In another example, the finding of exceptionally high levels of oxytocin in samples taken from ovarian cancers is particularly intriguing. Levels of oxytocin measured within tumors were associated with inflammatory markers, including IL-6, as well as patient survival. Thus, tissues challenged by cancer may produce healing levels of oxytocin (Cuneo et al., 2019).

However, the effect of oxytocin may not be universally beneficial. For example, there is conflicting evidence from several studies that prostate cancer, breast cancer, uterine cancer, and osteosarcomas can be either increased or decreased by oxytocin (Lerman et al., 2018). Among the types of cancer for which there are indications that exogenous oxytocin can increase proliferation and thus could be dangerous are prostate, uterine, and small cell lung cancer.

The complex relationships between oxytocin and cancer provide insight into the specificity of oxytocin’s effects. The local availability of oxytocin or its receptor, the tumor cell type, and the differential activation of subcellular signaling pathways downstream of OXTR can give rise to a unique oxytocin effect. For instance, there are three different subtypes of the guanine nucleotide–binding protein–α (Gα) (Gαi, Gαs, and Gαq) that couple to OXTR and that have separable functions. Gαq has been implicated in muscle contractions and cellular proliferation, whereas Gαi and Gαs may be antiproliferative (Lerman et al., 2018). Thus, effects on different subcellular signaling pathways could have opposite effects on cancer. Observations like these illustrate the challenges for creating drugs that optimize the benefits of oxytocin while reducing risks.

XIX. Pharmacology and Oxytocin: Issues in Therapeutic Applications

A. The Effects of Oxytocin Are Dose-Dependent

Doses of oxytocin currently used in human research have been restricted by availability and reliable access. Moreover, doses that were available were based on historical applications of oxytocin as an intranasal “lactational aid” or as an intravenous treatment in labor induction. Both of these applications were originally used in women who were pregnant or who had just given birth. Whether these doses and treatment regimens extrapolate to men and nonpregnant subjects, including children, is not well-studied.

Studies using different amounts of oxytocin are needed to examine possible threshold differences among individuals as a function of sex, experience, and emotional lability (Goldman et al., 2011). Different doses of a given peptide can produce different effects (Ceanga et al., 2010; Klein et al., 2014; Borland et al., 2019), and dose-response curves are only just appearing in the in vivo literature (Price et al., 2017).

B. Individual and Sex Differences Are to Be Expected in Both the Production of and Response to Oxytocin

As discussed above, the production of oxytocin varies among individuals, between males and females (Borland et al., 2019), and across the lifespan as well as in the capacity to respond to either endogenous or exogenous hormones (Plasencia et al., 2019). For example, studies of the effects of oxytocin on neural responses measured by functional magnetic resonance imaging have revealed marked sex differences in the effects of even a single intranasal treatment (Domes et al., 2010). Connectivity in the orbital frontal cortex, which is important in emotion processing, was correlated with oxytocin in women and vasopressin in men (Rubin et al., 2018). The developmental effects of these peptides are of special concern and are different in males and females (Carter, 2003; Bales et al., 2007) and in the face of adversity and stressful experiences.

C. The Basic Biochemistry of Oxytocin, Including Its Capacity to Bond to Other Molecules, Creates Special Challenges

The crosstalk between oxytocin, vasopressin, and their receptors (Figs. 2 and 3) has complicated attempts to create a medicine based on one or the other of these peptides (Caldwell, 2017; Carter, 2017; Song and Albers, 2018; Wang et al., 2019). The evolutionary basis of the oxytocin-vasopressin system permits a large number of functional permutations and creates significant obstacles to the creation of “medicines” based on these molecules. These interactions need to be considered if oxytocin-based molecules are to be used as the basis of a medicine (Feng et al., 2015; Li et al., 2017a). Moreover, as discussed here, developing effective pharmaceuticals based on oxytocin requires awareness of functional issues associated with oxytocin-vasopressin interactions and the biologic factors through which experience alters the functions of these molecules. As just one example, as described above, our research in prairie voles has revealed that small changes in experience or hormonal exposure, especially in early life,
have epigenetic consequences for the expression of Oxtr (Kenkel et al., 2019; Perkeybile et al., 2019).

**XX. Methods for Administering Oxytocin or Stimulating the Oxytocin System**

Studies of the effects of peripherally administered oxytocin offered a new perspective on the role of oxytocin in human behavior and aroused great interest in therapeutic applications of oxytocin (Kosfeld et al., 2005; Macdonald and Feifel, 2013). Dozens of clinical trials are now examining the functional effects ofOXTR agonists, including oxytocin and related drugs, such as the selective oxytocin receptor agonist carbetocin. Clinical studies typically report positive outcomes in at least a subset of patients.

In behavioral studies oxytocin has been most typically administered by intranasal spray. However, the behavioral effects of oxytocin have been questioned by complex findings from those studies, as detailed in many reviews (De Dreu, 2012; Macdonald and Feifel, 2013; Bethlehem et al., 2014; Bernaerts et al., 2017; Hurlemann and Grinevich, 2018). Moreover, even trials based on the classic nine–amino acid oxytocin molecule are often limited by the use of acute treatment protocols; in most cases a single treatment is used. Analysis of repeated and long-term effects of oxytocin or oxytocin-like molecules are rare, although even in adults, the effects of oxytocin-like drugs differ by the duration and dose used, and the effects may last for weeks beyond the time of treatment (Moy et al., 2019). Interpretation of these findings needs to be considered in the context of early life experience and the capacity of oxytocin to interact with vasopressin receptors (Carter, 2017) as well as other features of oxytocin’s functions detailed in the current review.

**A. Does Peripherally Administered Oxytocin Reach the Brain?**

In its classic nine–amino acid form, it was traditionally argued that oxytocin did not readily cross the blood-brain barrier (Leng and Ludwig, 2016). However, in studies done in monkeys, intranasally administered oxytocin labeled with deuterium was detected in cerebrospinal fluid (Lee et al., 2018) and in brain regions where oxytocin activity influences motivated behaviors (Lee et al., 2020). This argument also is diminished by recent awareness of the capacity of RAGE to act as an oxytocin-binding protein facilitating the transport of oxytocin across the blood-brain barrier and through other tissues (Yamamoto and Higashida, 2020). RAGE exists in a soluble form in blood and is also bound to cell membranes. Of particular interest to the functions of oxytocin, the directionality of this transport is 5–10 times higher from the blood to the brain, in comparison with brain to blood transport. Furthermore, RAGE is a member of the immunoglobulin superfamily with a role in regulating inflammation—once more implicating oxytocin in the body’s adaptive response to immune challenges (Figs. 4 and 5).

Imaging studies in rats comparing the effects of oxytocin given intravenously versus intracerebral infusion revealed that these two methods had very different consequences for blood oxygen level–dependent activity within the nervous system (Ferris et al., 2015). Imaging studies in humans also reveal that different methods of administration of oxytocin can produce different outcomes. For example, intranasal spray versus a nebulizer elicited responses, albeit in different brain areas and possibly in different regions of the olfactory tract (Martins et al., 2020). These findings support the potential usefulness of intranasal administration but leave the mechanisms of action open to further investigation. It also remains to be determined which methods of administration of exogenous oxytocin might be most functionally comparable to the effects of endogenously released peptides.

**B. Placental Transport of Oxytocin**

The weak penetrance of oxytocin through both the placenta and blood-brain barrier has been used as a justification for the wide use of Pitocin in labor induction. However, the evidence for transplacental passage of oxytocin has been mixed, with both positive and negative results reported [reviewed Kenkel et al. (2014)]. Interestingly, levels of oxytocin in cord blood measured within 1 minute of birth were significantly elevated in infants born via a vaginal birth (without maternal exogeneous oxytocin administration) as compared with infants born via elective cesarean section before labor started (Marchini et al., 1988). Further complicating understanding of their mechanisms of action, peptide receptors exist throughout the viscera, such as in the digestive tract (Welch et al., 2014). These receptors may allow oxytocin-like molecules to stimulate vagal afferents, thereby circumventing the blood-brain barrier in the transmission of information back to the brain.

**C. Oral Oxytocin**

Oxytocin is present in milk, and oral treatments with oxytocin, especially in young animals, may be an important route for influencing this system. Recent research in mice demonstrates that oxytocin is resistant to digestion (Yamamoto and Higashida, 2020) and is active in milk and colostrum, with effects on brain and behavior, especially in preweaning animals (Welch et al., 2014; Higashida et al., 2017; Klein et al., 2018; Tabbaa and Hammock, 2020). For example, Tabbaa and Hammock (2020) report that orally administered oxytocin affects the nervous system in young mice. Furthermore, RAGE transports oxytocin readily across the intestinal epithelium during the first postnatal week in mice when the intestinal barrier is still fairly permeable.
(Higashida et al., 2017). Although oxytocin absorption from the gut lumen to the blood can occur in adults, a 10-fold higher concentration of oxytocin is required (Higashida et al., 2017). As described above, comparable processes that are dependent on RAGE appear to occur in the nervous system, permitting crossing of the blood-brain barrier (Yamamoto et al., 2019). Knowledge of RAGE suggests yet another method for regulating the availability of and transport of oxytocin (Yamamoto and Higashida, 2020). For example, individual differences in RAGE could help to predict cellular access to oxytocin and might also facilitate access to oxytocin under conditions of stress or illness (Higashida et al., 2018; Yamamoto et al., 2019).

D. Increasing the Bioavailability of Oxytocin

Recent studies using methods to increase oxytocin’s access to the nervous system have employed nanoparticle encapsulation (Oppong-Damoah et al., 2019). This method of drug-delivery increases bioavailability of the oxytocin molecule both in cell-culture models of the blood-brain barrier and in a mouse model of social behavior. Intranasal application of nanoparticle-encapsulated of oxytocin had larger prosocial effects and behavioral changes that were sustained for at least 3 days after treatment. It is likely that new methods for delivering oxytocin will have dramatic effects on this field in the near future (Gulliver et al., 2019).

XXI. Summary

Oxytocin has effects on the regulation of physiologic processes and emotional states associated with coping and healing, with increasing evidence for beneficial actions mediated by the autonomic and immune systems. Oxytocin has special relevance for mammals, linking individuals to each other, with beneficial effects on reproduction, social behavior, and stress coping. Endogenous oxytocin and vasopressin are integral components of the body’s capacity to cope with stress. However, the effects of exogenous oxytocin are context- and dose-dependent (Huang et al., 2014). In individuals with a history of extreme stress or trauma, the effects of oxytocin have been especially unpredictable (Walsh et al., 2018). The reasons for this are unclear, but it is possible that stimulation of the vasopressin receptor(s) occurs, producing more primitive forms of response, such as defensive behaviors or even behavioral or metabolic shutdown (Porges and Furman, 2011).

Oxytocin and its receptors are comparatively modern molecules with particular relevance in mammalian evolution, physiology, and social behaviors (Carter, 2014). Oxytocin, possibly acting via the autonomic nervous system, seems to play a central role in supportive relationships and psychologic safety, helping to protect and heal in the face of stress and adversity (Carter, 1998; Karelin and DeVries, 2011; Porges and Furman, 2011; Hinsey et al., 2016). As describe above, oxytocin also has powerful immune consequences (Figs. 4 and 5), may promote longevity, and could have played a central role in human evolution (Carter, 2014). However, attempts to create safe drugs based on this molecule must take into account oxytocin’s unique evolutionary history and complex integrative adaptive properties that span the physiologic and social realms.

Acknowledgments

We are very grateful to Katie Krol, Josh Danoff, and Pat Kratochwell for editorial assistance.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Carter, Kenkel, MacLean, Wilson, Perkebyile, Yee, Ferris, Nazario, Porges, Davis, Connelly, Kingsbury.

References

Arrowsmith S and Wray S (2018) Oxytocin as Medicine 855


historical perspectives, current research and multifaceted role in the hypothalamic-hypophysial system. *Pituitary* 19:345–353.


